<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">ploscomp</journal-id>
<journal-title-group>
<journal-title>PLOS Computational Biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1553-734X</issn>
<issn pub-type="epub">1553-7358</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pcbi.1006335</article-id>
<article-id pub-id-type="publisher-id">PCOMPBIOL-D-17-01796</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral transmission and infection</subject><subj-group><subject>Viral load</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Interferons</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Gastroenterology and hepatology</subject><subj-group><subject>Liver diseases</subject><subj-group><subject>Cirrhosis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial control</subject><subj-group><subject>Antimicrobial resistance</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Antimicrobial resistance</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Hepacivirus</subject><subj-group><subject>Hepatitis C virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Hepacivirus</subject><subj-group><subject>Hepatitis C virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Hepacivirus</subject><subj-group><subject>Hepatitis C virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Hepacivirus</subject><subj-group><subject>Hepatitis C virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Hepatitis viruses</subject><subj-group><subject>Hepatitis C virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Hepatitis viruses</subject><subj-group><subject>Hepatitis C virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Hepatitis viruses</subject><subj-group><subject>Hepatitis C virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral replication</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral structure</subject><subj-group><subject>Virions</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug therapy</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection</article-title>
<alt-title alt-title-type="running-head">Interferon improves DAA treatment of hepatitis C</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Venugopal</surname>
<given-names>Vishnu</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Padmanabhan</surname>
<given-names>Pranesh</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Raja</surname>
<given-names>Rubesh</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2145-9828</contrib-id>
<name name-style="western">
<surname>Dixit</surname>
<given-names>Narendra M.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Chemical Engineering, Indian Institute of Science, Bangalore, India</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Centre for Biosystems Science and Engineering, Indian Institute of Science, Bangalore, India</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Regoes</surname>
<given-names>Roland R.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>ETH Zurich, SWITZERLAND</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">narendra@iisc.ac.in</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>12</day>
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<month>7</month>
<year>2018</year>
</pub-date>
<volume>14</volume>
<issue>7</issue>
<elocation-id>e1006335</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>10</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>6</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-year>2018</copyright-year>
<copyright-holder>Venugopal et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pcbi.1006335"/>
<abstract>
<p>Direct-acting antiviral agents (DAAs) for hepatitis C treatment tend to fare better in individuals who are also likely to respond well to interferon-alpha (IFN), a surprising correlation given that DAAs target specific viral proteins whereas IFN triggers a generic antiviral immune response. Here, we posit a causal relationship between IFN-responsiveness and DAA treatment outcome. IFN-responsiveness restricts viral replication, which would prevent the growth of viral variants resistant to DAAs and improve treatment outcome. To test this hypothesis, we developed a multiscale mathematical model integrating IFN-responsiveness at the cellular level, viral kinetics and evolution leading to drug resistance at the individual level, and treatment outcome at the population level. Model predictions quantitatively captured data from over 50 clinical trials demonstrating poorer response to DAAs in previous non-responders to IFN than treatment-naïve individuals, presenting strong evidence supporting the hypothesis. Model predictions additionally described several unexplained clinical observations, viz., the percentages of infected individuals who 1) spontaneously clear HCV, 2) get chronically infected but respond to IFN-based therapy, and 3) fail IFN-based therapy but respond to DAA-based therapy, resulting in a comprehensive understanding of HCV infection and treatment. An implication of the causal relationship is that failure of DAA-based treatments may be averted by adding IFN, a strategy of potential use in settings with limited access to DAAs. A second, wider implication is that individuals with greater IFN-responsiveness would require shorter DAA-based treatment durations, presenting a basis and a promising population for response-guided therapy.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author summary</title>
<p>Treatment of hepatitis C virus (HCV) infection is seeing a paradigm shift with powerful drugs called direct-acting antiviral agents (DAAs) replacing earlier treatments involving interferon (IFN). DAAs target specific HCV proteins. IFN stimulates our immune response against HCV. The two should thus work independently. Surprisingly, DAAs appear to work better in individuals who also tend to respond well to IFN. We hypothesized here that responsiveness to DAAs and IFN are causally linked. IFN can suppress viral replication, preventing the development of resistance to DAAs and improve DAA treatments. Using a new multiscale mathematical model and analysis of a vast body of clinical data, we found strong evidence supporting this hypothesis. Leveraging the causal relationship, we suggest new ways of optimizing DAA treatments, potentially improving their efficacy, tolerability, affordability and access.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100009053</institution-id>
<institution>DBT India Alliance</institution>
</institution-wrap>
</funding-source>
<award-id>IA/S/14/1/501307</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2145-9828</contrib-id>
<name name-style="western">
<surname>Dixit</surname>
<given-names>Narendra M.</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>Funding for this work came from the Wellcome Trust/DBT India Alliance Senior Fellowship IA/S/14/1/501307 (NMD) URL: <ext-link ext-link-type="uri" xlink:href="http://www.wellcomedbt.org/" xlink:type="simple">http://www.wellcomedbt.org/</ext-link>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="6"/>
<table-count count="1"/>
<page-count count="26"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>PLOS Publication Stage</meta-name>
<meta-value>vor-update-to-uncorrected-proof</meta-value>
</custom-meta>
<custom-meta>
<meta-name>Publication Update</meta-name>
<meta-value>2018-07-24</meta-value>
</custom-meta>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Direct-acting antiviral agents (DAAs) are revolutionizing the treatment of chronic hepatitis C virus (HCV) infection. Sustained virological response (SVR) rates of over 90% have been achieved in recent clinical trials with all-oral DAA treatments lasting as short as 12 weeks, in striking contrast to the combination of pegylated interferon and ribavirin (PR), which elicited SVR rates of only ~50% with 24–48 weeks of treatment [<xref ref-type="bibr" rid="pcbi.1006335.ref001">1</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref002">2</xref>]. Indeed, DAAs are rapidly replacing PR as the treatment of choice for chronic HCV infection [<xref ref-type="bibr" rid="pcbi.1006335.ref002">2</xref>]. An intriguing feature of DAAs is the differential response they elicit in individuals who respond differently to PR: They seem to work better in individuals who also tend to be more responsive to PR. For instance, with the combination of the DAAs ledipasvir and sofosbuvir, SVR rates dropped from nearly 100% in treatment-naive individuals to ~87% in PR-experienced individuals infected with HCV genotype 1b [<xref ref-type="bibr" rid="pcbi.1006335.ref001">1</xref>]. This differential response appears more significant with the older generation of DAAs than the newer ones, but is evident across clinical trials and across DAAs (<xref ref-type="table" rid="pcbi.1006335.t001">Table 1</xref>). Treatment guidelines for those who previously failed PR treatment are different from treatment naïve patients [<xref ref-type="bibr" rid="pcbi.1006335.ref003">3</xref>]. Interferon (IFN) acts primarily by stimulating the innate immune response to HCV [<xref ref-type="bibr" rid="pcbi.1006335.ref004">4</xref>]. Ribavirin is thought to potentiate the activity of IFN [<xref ref-type="bibr" rid="pcbi.1006335.ref005">5</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref006">6</xref>]. DAAs, on the other hand, target specific HCV proteins, independently of host immune responses [<xref ref-type="bibr" rid="pcbi.1006335.ref007">7</xref>]. Why responsiveness to IFN should improve outcomes of DAA-based treatments is thus puzzling.</p>
<table-wrap id="pcbi.1006335.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006335.t001</object-id>
<label>Table 1</label> <caption><title>Response to DAA-based treatments.</title> <p>SVR rates elicited by various IFN-free and IFN-containing DAA combinations in treatment-naïve and prior null responders to PR from recent clinical trials. The treated population size is indicated in brackets. The significance of the difference in the SVR rates in the two populations is computed using the χ<sup>2</sup> test. The HCV genotype and whether the patients had liver cirrhosis is indicated. The details of the treatment regimens along with the sources of the data are in <xref ref-type="supplementary-material" rid="pcbi.1006335.s004">S1 Table</xref>.</p></caption>
<alternatives>
<graphic id="pcbi.1006335.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="center" rowspan="2">Regimen</th>
<th align="center" rowspan="2">Genotype</th>
<th align="center" rowspan="2">Cirrhosis</th>
<th align="center" colspan="2">% SVR (N)</th>
<th align="center" rowspan="2">P-value</th>
</tr>
<tr>
<th align="left"/>
<th align="left">Naïve</th>
<th align="left">Null</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" rowspan="9">IFN-containing regimen</td>
<td align="left" rowspan="3">Telaprevir + PR</td>
<td align="center">1</td>
<td align="center">nd<xref ref-type="table-fn" rid="t001fn001"><sup>$</sup></xref></td>
<td align="left">75.4 (1272)</td>
<td align="left">32 (147)</td>
<td align="left">5.2×10<sup>−28</sup></td>
</tr>
<tr>
<td align="center">1</td>
<td align="center">no</td>
<td align="left">68.7 (941)</td>
<td align="left">50.7 (213)</td>
<td align="left">6.7×10<sup>−7</sup></td>
</tr>
<tr>
<td align="center">1</td>
<td align="center">yes</td>
<td align="left">45.4 (291)</td>
<td align="left">26.6 (79)</td>
<td align="left">2.6×10<sup>−3</sup></td>
</tr>
<tr>
<td align="left" rowspan="2">Boceprevir + PR</td>
<td align="center">1</td>
<td align="center">no</td>
<td align="left">65.4 (1179)</td>
<td align="left">43.5 (85)</td>
<td align="left">5.0×10<sup>−5</sup></td>
</tr>
<tr>
<td align="center">1</td>
<td align="center">yes</td>
<td align="left">44.3 (140)</td>
<td align="left">0 (10)</td>
<td align="left">6.0×10<sup>−3</sup></td>
</tr>
<tr>
<td align="left" rowspan="4">Simeprevir + PR</td>
<td align="center">1</td>
<td align="center">no</td>
<td align="left">83.3 (684)</td>
<td align="left">49.6 (252)</td>
<td align="left">1.2×10<sup>−25</sup></td>
</tr>
<tr>
<td align="center">1</td>
<td align="center">yes</td>
<td align="left">60.4 (48)</td>
<td align="left">24.6 (61)</td>
<td align="left">1.5×10<sup>−4</sup></td>
</tr>
<tr>
<td align="center">1</td>
<td align="center">nd</td>
<td align="left">91.3 (150)</td>
<td align="left">52 (50)</td>
<td align="left">5.5×10<sup>−10</sup></td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">nd</td>
<td align="left">82.9 (35)</td>
<td align="left">40 (40)</td>
<td align="left">1.6×10<sup>−4</sup></td>
</tr>
<tr>
<td align="center" rowspan="23">IFN-free regimen</td>
<td align="left">Sofosbuvir + ribavirin</td>
<td align="center">1</td>
<td align="center">no</td>
<td align="left">84 (25)</td>
<td align="left">10 (10)</td>
<td align="left">4.3×10<sup>−5</sup></td>
</tr>
<tr>
<td align="left" rowspan="2">Simeprevir + sofosbuvir</td>
<td align="center">1</td>
<td align="center">no</td>
<td align="left">94.7 (226)</td>
<td align="left">94.1 (17)</td>
<td align="left">9.2×10<sup>−1</sup></td>
</tr>
<tr>
<td align="center">1</td>
<td align="center">yes</td>
<td align="left">86.4 (176)</td>
<td align="left">100 (4)</td>
<td align="left">4.3×10<sup>−1</sup></td>
</tr>
<tr>
<td align="left" rowspan="2">Ledipasvir + sofosbuvir</td>
<td align="center">1</td>
<td align="center">yes</td>
<td align="left">92.1 (573)</td>
<td align="left">70 (10)</td>
<td align="left">1.2×10<sup>−2</sup></td>
</tr>
<tr>
<td align="center">1</td>
<td align="center">nd</td>
<td align="left">99.1 (214)</td>
<td align="left">98.1 (49)</td>
<td align="left">2.2×10<sup>−3</sup></td>
</tr>
<tr>
<td align="left">Ledipasvir + sofosbuvir + ribavirin</td>
<td align="center">1</td>
<td align="center">nd</td>
<td align="left">97.2 (217)</td>
<td align="left">95.7 (46)</td>
<td align="left">5.7×10<sup>−1</sup></td>
</tr>
<tr>
<td align="left">Ombitasvir + paritaprevir/ritonavir + dasabuvir</td>
<td align="center">1</td>
<td align="center">no</td>
<td align="left">95.7 (983)</td>
<td align="left">100 (32)</td>
<td align="left">2.3×10<sup>−1</sup></td>
</tr>
<tr>
<td align="left" rowspan="2">Ombitasvir + paritaprevir/ritonavir + dasabuvir + ribavirin</td>
<td align="center">1</td>
<td align="center">no</td>
<td align="left">96.4 (1892)</td>
<td align="left">96.3 (188)</td>
<td align="left">9.3×10<sup>−1</sup></td>
</tr>
<tr>
<td align="center">1</td>
<td align="center">yes</td>
<td align="left">96.7 (418)</td>
<td align="left">86.7 (75)</td>
<td align="left">2.2×10<sup>−4</sup></td>
</tr>
<tr>
<td align="left" rowspan="3">Grazoprevir + elbasvir</td>
<td align="center">1</td>
<td align="center">yes</td>
<td align="left">96.4 (137)</td>
<td align="left">92.9 (14)</td>
<td align="left">5.2×10<sup>−1</sup></td>
</tr>
<tr>
<td align="center">1</td>
<td align="center">no</td>
<td align="left">92.9 (85)</td>
<td align="left">89.5 (19)</td>
<td align="left">6.1×10<sup>−1</sup></td>
</tr>
<tr>
<td align="center">1, 4 and 6</td>
<td align="center">nd</td>
<td align="left">94.4 (517)</td>
<td align="left">91.8 (49)</td>
<td align="left">4.7×10<sup>−1</sup></td>
</tr>
<tr>
<td align="left" rowspan="2">Grazoprevir + elbasvir + ribavirin</td>
<td align="center">1</td>
<td align="center">yes</td>
<td align="left">96.9 (32)</td>
<td align="left">90.9 (11)</td>
<td align="left">4.2×10<sup>−1</sup></td>
</tr>
<tr>
<td align="center">1</td>
<td align="center">no</td>
<td align="left">97.7 (44)</td>
<td align="left">100 (21)</td>
<td align="left">4.9×10<sup>−1</sup></td>
</tr>
<tr>
<td align="left">Paritaprevir/ritonavir + dasabuvir + ribavirin</td>
<td align="center">1</td>
<td align="center">no</td>
<td align="left">94.7 (19)</td>
<td align="left">47.1 (17)</td>
<td align="left">1.4×10<sup>−3</sup></td>
</tr>
<tr>
<td align="left">Ombitasvir + paritaprevir/ritonavir</td>
<td align="center">1b</td>
<td align="center">nd</td>
<td align="left">95.2 (42)</td>
<td align="left">89.7 (58)</td>
<td align="left">3.1×10<sup>−1</sup></td>
</tr>
<tr>
<td align="left">Daclatasvir + simeprevir</td>
<td align="center">1b</td>
<td align="center">nd</td>
<td align="left">84.9 (53)</td>
<td align="left">95 (20)</td>
<td align="left">2.4×10<sup>−1</sup></td>
</tr>
<tr>
<td align="left">Daclatasvir + simeprevir + ribavirin</td>
<td align="center">1b</td>
<td align="center">nd</td>
<td align="left">74.5 (51)</td>
<td align="left">69.6 (23)</td>
<td align="left">6.6×10<sup>−1</sup></td>
</tr>
<tr>
<td align="left" rowspan="2">Daclatasvir + asunaprevir</td>
<td align="center">1</td>
<td align="center">no</td>
<td align="left">89.5 (171)</td>
<td align="left">79.6 (142)</td>
<td align="left">1.5×10<sup>−2</sup></td>
</tr>
<tr>
<td align="center">1</td>
<td align="center">yes</td>
<td align="left">90.6 (32)</td>
<td align="left">87.3 (63)</td>
<td align="left">6.3×10<sup>−1</sup></td>
</tr>
<tr>
<td align="left">Sofosbuvir + radalbuvir + ribavirin</td>
<td align="center">1</td>
<td align="center">no</td>
<td align="left">92 (25)</td>
<td align="left">100 (10)</td>
<td align="left">3.6×10<sup>−1</sup></td>
</tr>
<tr>
<td align="left">Daclatasvir + asunaprevir + beclabuvir</td>
<td align="center">1</td>
<td align="center">no</td>
<td align="left">92.0 (312)</td>
<td align="left">88.0 (25)</td>
<td align="left">4.9×10<sup>−1</sup></td>
</tr>
<tr>
<td align="left">Daclatasvir + asunaprevir + beclabuvir ± ribavirin</td>
<td align="center">1</td>
<td align="center">yes</td>
<td align="left">95.5 (112)</td>
<td align="left">97.1 (35)</td>
<td align="left">6.8×10<sup>−1</sup></td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p><sup>$</sup>nd–not distinguished/determined</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Here, we hypothesized that the responsiveness of individuals to IFN and DAAs are causally linked. DAAs are susceptible to viral mutation-driven development of drug resistance [<xref ref-type="bibr" rid="pcbi.1006335.ref008">8</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref009">9</xref>]. Resistance-associated amino acid variants (RAVs) have been identified that possess high level resistance (&gt;1000-fold increase in EC<sub>50</sub>) to DAAs [<xref ref-type="bibr" rid="pcbi.1006335.ref009">9</xref>]. Given the rapid turnover of HCV <italic>in vivo</italic> [<xref ref-type="bibr" rid="pcbi.1006335.ref010">10</xref>] and its high mutation rate [<xref ref-type="bibr" rid="pcbi.1006335.ref011">11</xref>], RAVs are likely to pre-exist in chronically infected individuals [<xref ref-type="bibr" rid="pcbi.1006335.ref012">12</xref>] and/or arise during treatment [<xref ref-type="bibr" rid="pcbi.1006335.ref013">13</xref>], potentially lowering the efficacy of DAAs. Indeed, in retrospective analyses, RAVs were detected more frequently in individuals who failed DAA treatment than in those who achieved SVR [<xref ref-type="bibr" rid="pcbi.1006335.ref001">1</xref>]. With the combination of ledipasvir and sofosbuvir, for example, 16% of all the patients treated had detectable RAVs at baseline, whereas of those who suffered virological failure, 43% had detectable RAVs at baseline [<xref ref-type="bibr" rid="pcbi.1006335.ref014">14</xref>]. Although systematic resistance testing is not recommended, current treatment guidelines suggest resistance testing, where such testing is readily accessible and reliable, in the NS5A region to decide appropriate treatment regimens [<xref ref-type="bibr" rid="pcbi.1006335.ref003">3</xref>]. IFN, a cytokine produced in response to viral infections, triggers the expression of several hundred IFN-stimulated genes (ISGs) in infected cells, creating an antiviral state that restricts viral replication [<xref ref-type="bibr" rid="pcbi.1006335.ref004">4</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref015">15</xref>]. Higher responsiveness to IFN may thus restrict viral replication to a greater extent, exerting better control on RAVs and leading to improved outcomes of DAA-based treatments. This causal relationship may underlie the positive correlation between responsiveness to PR and DAAs observed in clinical trials. We tested this hypothesis using mathematical modelling and analysis of clinical data.</p>
<p>Mathematical models of HCV kinetics have played a crucial role in our understanding of HCV infection and guided treatments [<xref ref-type="bibr" rid="pcbi.1006335.ref016">16</xref>]. A model to test the hypothesis above had to address the following questions. 1) What is the origin of the differential responsiveness of HCV-infected individuals to IFN? 2) How can the IFN-responsiveness of an individual be quantified? 3) Given the IFN-responsiveness of an individual, how does the individual respond to DAAs, assuming the hypothesized causal link above? 4) How is IFN-responsiveness distributed across individuals in a population? 5) Does this latter distribution, coupled with the predicted responses of individuals to treatments, explain the differences in SVR rates between treatment-naive and treatment-experienced populations observed across DAAs and across clinical trials?</p>
<p>Existing models [<xref ref-type="bibr" rid="pcbi.1006335.ref005">5</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref010">10</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref012">12</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref017">17</xref>–<xref ref-type="bibr" rid="pcbi.1006335.ref027">27</xref>] have addressed some but not all of these questions. For instance, IFN-responsiveness has been shown recently to be an emergent property of the IFN signaling network in HCV infected cells [<xref ref-type="bibr" rid="pcbi.1006335.ref017">17</xref>]. Due to the competing interactions between ISGs and HCV [<xref ref-type="bibr" rid="pcbi.1006335.ref028">28</xref>–<xref ref-type="bibr" rid="pcbi.1006335.ref033">33</xref>], the network exhibits bistability, with one steady state responsive and the other refractory to IFN. The proportion of cells in an individual that preferentially assume the responsive state determines the IFN-responsiveness of the individual [<xref ref-type="bibr" rid="pcbi.1006335.ref017">17</xref>]. Although variations in ISG protein copy numbers and other factors across cells [<xref ref-type="bibr" rid="pcbi.1006335.ref025">25</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref034">34</xref>] and across individuals [<xref ref-type="bibr" rid="pcbi.1006335.ref035">35</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref036">36</xref>] and effects such as those attributed to the polymorphisms in the IL28B gene locus [<xref ref-type="bibr" rid="pcbi.1006335.ref037">37</xref>] that collectively result in different levels of IFN-responsiveness in different individuals have been identified, how IFN-responsiveness is distributed across individuals remains unknown. Inspired by the success of models in describing HIV drug resistance [<xref ref-type="bibr" rid="pcbi.1006335.ref038">38</xref>], similar models of HCV kinetics incorporating mutations and their fitness effects have been developed to estimate the pre-existing frequencies of RAVs in chronically HCV infected individuals and to predict their growth during treatment with DAAs [<xref ref-type="bibr" rid="pcbi.1006335.ref012">12</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref016">16</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref018">18</xref>–<xref ref-type="bibr" rid="pcbi.1006335.ref022">22</xref>]. The latter models, however, do not treat IFN-responsiveness as a factor influencing the pre-existence and growth of RAVs and hence treatment outcomes. Finally, no models, barring those invoking empirical correlations [<xref ref-type="bibr" rid="pcbi.1006335.ref020">20</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref039">39</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref040">40</xref>], have described SVR rates elicited by different DAA-based treatment regimens.</p>
<p>Constructing a mathematical model to test the proposed causal relationship thus faced two broad challenges. First, phenomena spanning multiple length and time scales–from the cellular to the population level–had to be integrated into a single mathematical framework. Second, several missing pieces in the puzzle, not considered by existing models, had to be identified. We developed a model that overcame both these challenges. Model predictions captured the vast body of clinical data of the differential response of patients to DAA-based treatments quantitatively, making a strong case for the proposed causal relationship. The model additionally explained several longstanding but poorly understood clinical observations, presenting a far more comprehensive understanding of HCV infection and treatment response than earlier. Finally, using the model, we suggest new strategies, exploiting the causal relationship, to improve DAA-based treatments.</p>
</sec>
<sec id="sec002" sec-type="results">
<title>Results</title>
<sec id="sec003">
<title>Correlation between responsiveness to PR and DAAs</title>
<p>To establish the correlation between the responsiveness of chronically HCV infected individuals to PR and DAAs, we collated data from all (over 50) clinical trials that reported SVR rates achieved with DAA-based treatments in treatment-naïve individuals, <italic>SVR</italic><sub><italic>naive</italic></sub>, and in previous null responders to PR, <italic>SVR</italic><sub><italic>null</italic></sub> (Methods). The data are grouped according to treatment regimen and summarized in <xref ref-type="table" rid="pcbi.1006335.t001">Table 1</xref>. Individual datasets are listed in <xref ref-type="supplementary-material" rid="pcbi.1006335.s004">S1 Table</xref>. We found that <italic>SVR</italic><sub><italic>naive</italic></sub>&gt;<italic>SVR</italic><sub><italic>null</italic></sub> with P≈10<sup>−59</sup> overall (using the χ<sup>2</sup>-test). The difference was starker when the analysis was restricted to treatments that included PR (P≈10<sup>−65</sup>), but, importantly, was highly significant when interferon-free regimens alone were considered (P = 0.007). The difference remained when only individuals with (<xref ref-type="supplementary-material" rid="pcbi.1006335.s005">S2 Table</xref>; P≈10<sup>−5</sup>) or without (<xref ref-type="supplementary-material" rid="pcbi.1006335.s006">S3 Table</xref>; P≈10<sup>−29</sup>) liver cirrhosis were considered or when the analysis was restricted to studies that did not factor liver cirrhosis (<xref ref-type="supplementary-material" rid="pcbi.1006335.s007">S4 Table</xref>; P≈10<sup>−30</sup>). The difference was clearer for treatments that elicited &lt;100% SVR than for more recent, stronger treatments that elicited ~100% SVR regardless of treatment experience. Nonetheless, the clinical evidence of a positive correlation between responsiveness to PR and DAAs was overwhelming and suggested a causal relationship between the two. We proposed a mechanistic hypothesis underlying this relationship, where greater IFN-responsiveness exerted better control on RAVs and improved DAA treatment outcomes (see above), and constructed a mathematical model to test it.</p>
</sec>
<sec id="sec004">
<title>Mathematical model</title>
<p>We present an overview of the model here (<xref ref-type="fig" rid="pcbi.1006335.g001">Fig 1</xref>). A detailed description of the various components of our model and how we integrated them into a single framework is in Methods.</p>
<fig id="pcbi.1006335.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006335.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Schematic of the model.</title>
<p><bold>(A)</bold> Hepatocytes in an HCV infected individual display a range of phenotypic responses to IFN, from refractory (red) to responsive (blue). <bold>(B)</bold> Different individuals carry different fractions of hepatocytes displaying these distinct responses, yielding a distribution of IFN-responsiveness in an HCV infected population. Individuals with a small proportion of IFN-refractory hepatocytes respond to treatment (left inset), whereas those with a large proportion see virologic breakthrough due to the growth of drug resistant (RAV) and/or wild-type (WT) strains (right inset). <bold>(C)</bold> The threshold or admissible proportion of IFN-refractory hepatocytes depends on the drugs and treatment protocol employed and defines the SVR rate the treatment elicits in a population.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.g001" xlink:type="simple"/>
</fig>
<p>To describe the response of an individual to PR, we employed the formalism we developed previously, where cells were divided into distinct IFN-responsive and IFN-refractory phenotypes based on the properties of the IFN-signaling network in HCV-infected cells [<xref ref-type="bibr" rid="pcbi.1006335.ref017">17</xref>]. At the cellular level, interferon triggers the expression of several hundred interferon-stimulated genes (ISGs) that collectively create an antiviral state in cells [<xref ref-type="bibr" rid="pcbi.1006335.ref015">15</xref>]. HCV suppresses the interferon response via multiple mechanisms [<xref ref-type="bibr" rid="pcbi.1006335.ref004">4</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref041">41</xref>], the prominent one involving a block in ISG translation it induces via dimerization and autophosphorylation of protein kinase R [<xref ref-type="bibr" rid="pcbi.1006335.ref030">30</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref042">42</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref043">43</xref>]. We constructed a comprehensive model of the IFN signaling network in the presence of HCV, accounting for the competing effects above which amounted to a double negative feedback, and found that the network exhibited bistability [<xref ref-type="bibr" rid="pcbi.1006335.ref017">17</xref>]. In one steady state, HCV overcame the IFN response and established lasting infection. In the other, IFN cleared HCV. Intrinsic variations of the factors defining the IFN signaling network, which defined the strength of the IFN response relative to the strength of its subversion by HCV, resulted in individual cells admitting either one or both the states. Cells that admitted the first steady state alone were refractory to IFN. Cells that admitted the latter alone were responsive to IFN. Cells that admitted both were bistable and the state they eventually realized depended on whether they were exposed earlier to HCV or IFN.</p>
<p>Based on the description above, we divided cells in an individual into three distinct IFN-response phenotypes, IFN-refractory, bistable, and IFN-responsive. With this classification, we constructed a model of viral kinetics that described viral load changes in individuals following the onset of PR treatment. HCV thrived in the IFN-refractory compartment despite exposure to PR. The relative proportion of cells that were of the IFN-refractory phenotype thus quantified the IFN-responsiveness of individuals. By increasing this proportion, which decreased IFN-responsiveness, the formalism was shown to quantitatively capture the observed patterns of viral load decline, from rapid response to null response, in patients undergoing PR treatment [<xref ref-type="bibr" rid="pcbi.1006335.ref017">17</xref>].</p>
<p>To describe the pre-existence and growth of RAVs under DAA-based treatment, we built on previous models of viral kinetics and evolution [<xref ref-type="bibr" rid="pcbi.1006335.ref012">12</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref016">16</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref018">18</xref>–<xref ref-type="bibr" rid="pcbi.1006335.ref022">22</xref>], which have provided good fits to patient data of wild-type and RAV population dynamics [<xref ref-type="bibr" rid="pcbi.1006335.ref012">12</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref016">16</xref>]. The models allowed mutations, which occurred during viral replication, at specific loci to confer resistance to DAAs. The mutations, however, came with fitness costs. The models could thus predict the pre-existing frequencies of RAVs and their growth rates during treatment with DAAs. We combined the models above by integrating the distinct cellular phenotypes with viral kinetics and evolution to arrive at a description of the response of an individual to DAA-based treatments and the influence IFN has on the response. The poorer the IFN-responsiveness of an individual, the greater the level of ongoing replication during treatment, and hence the higher the likelihood of the development of resistance to DAAs. The combined model thus yielded threshold levels of IFN-responsiveness required for treatments to succeed.</p>
<p>We next developed independent descriptions of the distribution of IFN-responsiveness in populations. We showed that the pre-treatment set-point viral load was directly related to the IFN-responsiveness of an individual, allowing us to quantify the distribution of IFN-responsiveness using measurements of viral load in populations. The fraction of individuals with IFN-responsiveness above the threshold IFN-responsiveness predicted above for any treatment yielded the SVR rates elicited by that treatment. In particular, the threshold for a null response to PR yielded the percentage of null responders and hence, truncating the distribution above to the latter threshold, the distribution of IFN-responsiveness in null responders to PR. Linking the distribution of IFN-responsiveness in populations to the individual-level models of viral kinetics and treatment response thus allowed estimation of SVR rates across different populations, particularly treatment naïve and previous null responders to PR, elicited by different treatment regimens.</p>
</sec>
<sec id="sec005">
<title>Pre-treatment RAV frequencies</title>
<p>We applied the model first to examine whether greater IFN-responsiveness lowered the pre-existence of RAVs in infected individuals (<xref ref-type="fig" rid="pcbi.1006335.g002">Fig 2</xref>). We quantified the IFN-responsiveness of an individual by the fraction of target cells produced in the individual that exhibited the IFN-refractory phenotype [<xref ref-type="bibr" rid="pcbi.1006335.ref017">17</xref>], denoted <inline-formula id="pcbi.1006335.e001"><alternatives><graphic id="pcbi.1006335.e001g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e001" xlink:type="simple"/><mml:math display="inline" id="M1"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. The smaller the value of <inline-formula id="pcbi.1006335.e002"><alternatives><graphic id="pcbi.1006335.e002g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e002" xlink:type="simple"/><mml:math display="inline" id="M2"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, the more IFN-responsive was the individual. Using our model, we estimated the steady state pre-treatment populations of wild-type and RAV-carrying virions, <italic>V</italic><sub>0</sub> and <italic>V</italic><sub>1</sub>, respectively, and the frequency, <italic>ρ</italic><sub>1</sub> = <italic>V</italic><sub>1</sub>/(<italic>V</italic><sub>0</sub>+<italic>V</italic><sub>1</sub>), of RAVs, as functions of <inline-formula id="pcbi.1006335.e003"><alternatives><graphic id="pcbi.1006335.e003g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e003" xlink:type="simple"/><mml:math display="inline" id="M3"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> (Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>), Methods). A single point mutation was assumed first to confer resistance to the DAA. Mutation occurred at the rate <italic>μ</italic> and allowed the production of <italic>V</italic><sub>1</sub> from cells infected with <italic>V</italic><sub>0</sub>. The mutations came with a fitness cost to the virus, determined by lower values of viral infectivity and/or productivity, <italic>γ</italic>, relative to the wild-type. We found that <italic>ρ</italic><sub>1</sub> was independent of <inline-formula id="pcbi.1006335.e004"><alternatives><graphic id="pcbi.1006335.e004g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e004" xlink:type="simple"/><mml:math display="inline" id="M4"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> (<xref ref-type="fig" rid="pcbi.1006335.g002">Fig 2A</xref>). As <inline-formula id="pcbi.1006335.e005"><alternatives><graphic id="pcbi.1006335.e005g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e005" xlink:type="simple"/><mml:math display="inline" id="M5"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> increased, fewer cells were IFN-responsive, which resulted in an increase in <italic>V</italic><sub>1</sub> (<xref ref-type="fig" rid="pcbi.1006335.g002">Fig 2C</xref>). However, of the virions produced (<xref ref-type="fig" rid="pcbi.1006335.g002">Fig 2B and 2C</xref>), a constant fraction, determined by the mutation rate, <italic>μ</italic>, and the relative fitness of the RAV, <italic>γ</italic>, carried the RAV, leaving <italic>ρ</italic><sub>1</sub> unaffected. Further, both <italic>V</italic><sub>1</sub> and <italic>ρ</italic><sub>1</sub> but not <italic>V</italic><sub>0</sub> increased significantly with <italic>μ</italic> and <italic>γ</italic> (<xref ref-type="fig" rid="pcbi.1006335.g002">Fig 2A–2C</xref>). We derived analytical approximations (<xref ref-type="supplementary-material" rid="pcbi.1006335.s009">S1 Text</xref>) that quantitatively explained these variations (<xref ref-type="fig" rid="pcbi.1006335.g002">Fig 2A–2C</xref>). The results were readily extended to multiple loci (<xref ref-type="supplementary-material" rid="pcbi.1006335.s010">S2</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006335.s011">S3 Texts</xref>; <xref ref-type="fig" rid="pcbi.1006335.g002">Fig 2D–2G</xref>).</p>
<fig id="pcbi.1006335.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006335.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Pre-treatment frequencies and populations of virions.</title>
<p>Model predictions (lines) and analytical approximations (symbols) (<xref ref-type="supplementary-material" rid="pcbi.1006335.s009">S1</xref>–<xref ref-type="supplementary-material" rid="pcbi.1006335.s011">S3 Texts</xref>) of the mutant frequencies (left) and viral populations (right) in the pre-treatment steady state as a function of the level of IFN-responsiveness, <inline-formula id="pcbi.1006335.e006"><alternatives><graphic id="pcbi.1006335.e006g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e006" xlink:type="simple"/><mml:math display="inline" id="M6"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, for different combinations of the mutation rate, <italic>μ</italic>, and the relative fitness of the RAV, <italic>γ</italic>: (<italic>μ</italic>,<italic>γ</italic>) = (3×10<sup>−4</sup>,0.9) (blue), (3×10<sup>−4</sup>,0.8) (red), (3×10<sup>−4</sup>,0.7) (green) and (3×10<sup>−5</sup>,0.8) (black). Here, <italic>γ</italic> = <italic>p</italic><sub>1</sub>/<italic>p</italic><sub>0</sub>, the ratio of the viral production rates, or equivalently the replicative abilities, of the mutant and wild-type strains; without loss of generality, the RAV was assumed not to compromise viral infectivity (see <xref ref-type="supplementary-material" rid="pcbi.1006335.s009">S1</xref>–<xref ref-type="supplementary-material" rid="pcbi.1006335.s011">S3 Texts</xref>). Single mutant frequencies (<bold>A)</bold> and the populations of wild-type <bold>(B)</bold> and single mutant <bold>(C)</bold> virions when the genetic barrier is 1. Double mutant frequencies <bold>(D)</bold> and the populations of wild-type <bold>(E)</bold>, single mutant <bold>(F)</bold>, and double mutant <bold>(G)</bold> virions when the genetic barrier is 2. In the latter case, the two single mutants have the same relative fitness, <italic>γ</italic>, and the double mutant, <italic>γ</italic><sup>2</sup>. In (B) and (E), the different lines and symbols are indistinguishable. Parameter values employed are in <xref ref-type="supplementary-material" rid="pcbi.1006335.s008">S5 Table</xref>. The parameters to which these predictions are sensitive are as expected from the analytical approximations (<xref ref-type="supplementary-material" rid="pcbi.1006335.s001">S1 Fig</xref>).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.g002" xlink:type="simple"/>
</fig>
<p>Thus, greater IFN-responsiveness did not significantly alter the pre-treatment frequencies of RAVs, although it did lead to lower pre-treatment viral loads and populations of RAVs, indicating greater control over ongoing viral replication. This greater control could influence the growth of RAVs during treatment with DAAs, which we examined next.</p>
</sec>
<sec id="sec006">
<title>Growth of RAVs during IFN-free treatment</title>
<p>We predicted the viral load decline under DAA treatment for a range of treatment efficacies against the wild-type, <inline-formula id="pcbi.1006335.e007"><alternatives><graphic id="pcbi.1006335.e007g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e007" xlink:type="simple"/><mml:math display="inline" id="M7"><mml:mrow><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mo>≤</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, and the RAV, <inline-formula id="pcbi.1006335.e008"><alternatives><graphic id="pcbi.1006335.e008g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e008" xlink:type="simple"/><mml:math display="inline" id="M8"><mml:mrow><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup><mml:mo>≤</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, and for different fitness penalties, <italic>γ</italic>, associated with the RAV (Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>), Methods). We defined the effective relative fitness of the RAV during treatment as <inline-formula id="pcbi.1006335.e009"><alternatives><graphic id="pcbi.1006335.e009g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e009" xlink:type="simple"/><mml:math display="inline" id="M9"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>γ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, combining the intrinsic fitness disadvantage of the RAV and its advantage in the presence of the drug. We defined <inline-formula id="pcbi.1006335.e010"><alternatives><graphic id="pcbi.1006335.e010g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e010" xlink:type="simple"/><mml:math display="inline" id="M10"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> as the IFN-responsiveness during treatment. <inline-formula id="pcbi.1006335.e011"><alternatives><graphic id="pcbi.1006335.e011g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e011" xlink:type="simple"/><mml:math display="inline" id="M11"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> depended on the total IFN exposure, the sum of endogenous and exogenous levels [<xref ref-type="bibr" rid="pcbi.1006335.ref017">17</xref>]. For IFN-free treatments, where exogenous IFN is absent, we let <inline-formula id="pcbi.1006335.e012"><alternatives><graphic id="pcbi.1006335.e012g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e012" xlink:type="simple"/><mml:math display="inline" id="M12"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> (Methods). We found that the response to treatment was determined predominantly by <inline-formula id="pcbi.1006335.e013"><alternatives><graphic id="pcbi.1006335.e013g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e013" xlink:type="simple"/><mml:math display="inline" id="M13"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pcbi.1006335.e014"><alternatives><graphic id="pcbi.1006335.e014g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e014" xlink:type="simple"/><mml:math display="inline" id="M14"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> and <italic>γ</italic><sub><italic>t</italic></sub> (<xref ref-type="fig" rid="pcbi.1006335.g003">Fig 3</xref>). With high <inline-formula id="pcbi.1006335.e015"><alternatives><graphic id="pcbi.1006335.e015g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e015" xlink:type="simple"/><mml:math display="inline" id="M15"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mo>∼</mml:mo><mml:mn>0.99</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, the wild-type could be cleared by the DAA regardless of <inline-formula id="pcbi.1006335.e016"><alternatives><graphic id="pcbi.1006335.e016g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e016" xlink:type="simple"/><mml:math display="inline" id="M16"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. Then, for any <italic>γ</italic><sub><italic>t</italic></sub>, the decline of the RAVs was faster for lower <inline-formula id="pcbi.1006335.e017"><alternatives><graphic id="pcbi.1006335.e017g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e017" xlink:type="simple"/><mml:math display="inline" id="M17"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. Below a critical value of <inline-formula id="pcbi.1006335.e018"><alternatives><graphic id="pcbi.1006335.e018g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e018" xlink:type="simple"/><mml:math display="inline" id="M18"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, SVR was achieved, whereas above this critical value, virological breakthrough occurred (<xref ref-type="fig" rid="pcbi.1006335.g003">Fig 3A and 3C</xref>). Similarly, for a fixed <inline-formula id="pcbi.1006335.e019"><alternatives><graphic id="pcbi.1006335.e019g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e019" xlink:type="simple"/><mml:math display="inline" id="M19"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, RAVs declined faster for lower <italic>γ</italic><sub><italic>t</italic></sub> (<xref ref-type="fig" rid="pcbi.1006335.g003">Fig 3A and 3B</xref>). A locus of points on a <inline-formula id="pcbi.1006335.e020"><alternatives><graphic id="pcbi.1006335.e020g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e020" xlink:type="simple"/><mml:math display="inline" id="M20"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> plot delineated the region where SVR occurred from that where virological failure resulted due to drug resistance (<xref ref-type="fig" rid="pcbi.1006335.g003">Fig 3A</xref>). For lower <inline-formula id="pcbi.1006335.e021"><alternatives><graphic id="pcbi.1006335.e021g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e021" xlink:type="simple"/><mml:math display="inline" id="M21"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, breakthrough occurred at higher <italic>γ</italic><sub><italic>t</italic></sub>, indicating that higher degrees of resistance were necessary for virological breakthrough with higher IFN-responsiveness.</p>
<fig id="pcbi.1006335.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006335.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Response to IFN-free DAA treatment.</title>
<p><bold>(A)</bold> Phase diagram indicating regimes of the level of IFN-responsiveness, <inline-formula id="pcbi.1006335.e022"><alternatives><graphic id="pcbi.1006335.e022g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e022" xlink:type="simple"/><mml:math display="inline" id="M22"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, and the relative fitness of the RAV during treatment, <italic>γ</italic><sub><italic>t</italic></sub>, that lead to SVR (dark blue) or treatment failure due to virological breakthrough by the RAV (light blue). <bold>(B,C)</bold> Dynamics of wild-type (solid) and RAV (dashed) viral populations following treatment initiation for different parameter combinations numbered in (A). Here, the efficacy of treatment against the wild-type is assumed to be high: <inline-formula id="pcbi.1006335.e023"><alternatives><graphic id="pcbi.1006335.e023g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e023" xlink:type="simple"/><mml:math display="inline" id="M23"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.99</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. Also, <italic>γ</italic> = 0.2. <bold>(D)</bold> Phase diagram with lower efficacy, <inline-formula id="pcbi.1006335.e024"><alternatives><graphic id="pcbi.1006335.e024g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e024" xlink:type="simple"/><mml:math display="inline" id="M24"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.9</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, showing regions leading to SVR (dark blue) or treatment failure due to the RAV (light blue), wild-type (green), or both (brown). <bold>(E,F)</bold> Dynamics of wild-type (solid) and RAV (dashed) viral populations for the points numbered in (D). Here, <italic>γ</italic> = 0.4. Other parameter values employed are in <xref ref-type="supplementary-material" rid="pcbi.1006335.s008">S5 Table</xref>. Phase diagrams for other values of <inline-formula id="pcbi.1006335.e025"><alternatives><graphic id="pcbi.1006335.e025g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e025" xlink:type="simple"/><mml:math display="inline" id="M25"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> are in <xref ref-type="supplementary-material" rid="pcbi.1006335.s002">S2 Fig</xref>.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.g003" xlink:type="simple"/>
</fig>
<p>With lower <inline-formula id="pcbi.1006335.e026"><alternatives><graphic id="pcbi.1006335.e026g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e026" xlink:type="simple"/><mml:math display="inline" id="M26"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, the DAA was not potent enough to suppress the wild-type at all <inline-formula id="pcbi.1006335.e027"><alternatives><graphic id="pcbi.1006335.e027g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e027" xlink:type="simple"/><mml:math display="inline" id="M27"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. With <inline-formula id="pcbi.1006335.e028"><alternatives><graphic id="pcbi.1006335.e028g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e028" xlink:type="simple"/><mml:math display="inline" id="M28"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> large and <italic>γ</italic><sub><italic>t</italic></sub> small (&lt;1), the wild-type drove failure (<xref ref-type="fig" rid="pcbi.1006335.g003">Fig 3D and 3F</xref>). The value of <inline-formula id="pcbi.1006335.e029"><alternatives><graphic id="pcbi.1006335.e029g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e029" xlink:type="simple"/><mml:math display="inline" id="M29"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> above which failure occurred decreased as <inline-formula id="pcbi.1006335.e030"><alternatives><graphic id="pcbi.1006335.e030g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e030" xlink:type="simple"/><mml:math display="inline" id="M30"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> decreased, indicating that failure occurred even with higher IFN-responsiveness as the DAA efficacy dropped (<xref ref-type="fig" rid="pcbi.1006335.g003">Fig 3A and 3D</xref>). Conversely, poorer IFN-responsiveness placed more stringent demands on the DAA. As <italic>γ</italic><sub><italic>t</italic></sub> increased, both the wild-type and RAV co-existed during treatment failure and when <italic>γ</italic><sub><italic>t</italic></sub> rose above ~1, the RAV outcompeted the wild-type and drove treatment failure (<xref ref-type="fig" rid="pcbi.1006335.g003">Fig 3D and 3E</xref>).</p>
</sec>
<sec id="sec007">
<title>Growth of RAVs during PR+DAA treatment</title>
<p>With exogenous IFN present, <inline-formula id="pcbi.1006335.e031"><alternatives><graphic id="pcbi.1006335.e031g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e031" xlink:type="simple"/><mml:math display="inline" id="M31"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. We therefore let <inline-formula id="pcbi.1006335.e032"><alternatives><graphic id="pcbi.1006335.e032g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e032" xlink:type="simple"/><mml:math display="inline" id="M32"><mml:mrow><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>≤</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006335.e033"><alternatives><graphic id="pcbi.1006335.e033g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e033" xlink:type="simple"/><mml:math display="inline" id="M33"><mml:mrow><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup><mml:mo>≤</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> (<xref ref-type="fig" rid="pcbi.1006335.g004">Fig 4</xref>). For fixed <inline-formula id="pcbi.1006335.e034"><alternatives><graphic id="pcbi.1006335.e034g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e034" xlink:type="simple"/><mml:math display="inline" id="M34"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, <italic>γ</italic><sub><italic>t</italic></sub> and <inline-formula id="pcbi.1006335.e035"><alternatives><graphic id="pcbi.1006335.e035g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e035" xlink:type="simple"/><mml:math display="inline" id="M35"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, RAVs declined faster for lower <inline-formula id="pcbi.1006335.e036"><alternatives><graphic id="pcbi.1006335.e036g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e036" xlink:type="simple"/><mml:math display="inline" id="M36"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> (<xref ref-type="fig" rid="pcbi.1006335.g004">Fig 4B</xref>). Again, a threshold <inline-formula id="pcbi.1006335.e037"><alternatives><graphic id="pcbi.1006335.e037g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e037" xlink:type="simple"/><mml:math display="inline" id="M37"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> existed below which SVR was achieved and above which RAVs drove virological breakthrough when <inline-formula id="pcbi.1006335.e038"><alternatives><graphic id="pcbi.1006335.e038g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e038" xlink:type="simple"/><mml:math display="inline" id="M38"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> was high (<xref ref-type="fig" rid="pcbi.1006335.g004">Fig 4A</xref>). This threshold was weakly sensitive to <inline-formula id="pcbi.1006335.e039"><alternatives><graphic id="pcbi.1006335.e039g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e039" xlink:type="simple"/><mml:math display="inline" id="M39"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> because pre-treatment variations were rapidly subsumed post treatment initiation by the dynamics dictated by <inline-formula id="pcbi.1006335.e040"><alternatives><graphic id="pcbi.1006335.e040g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e040" xlink:type="simple"/><mml:math display="inline" id="M40"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> (<xref ref-type="fig" rid="pcbi.1006335.g004">Fig 4B</xref>). The threshold, however, was sensitive to <italic>γ</italic><sub><italic>t</italic></sub>. As <italic>γ</italic><sub><italic>t</italic></sub> increased, the threshold dropped, indicating that treatment failure occurred even with higher IFN-responsiveness as the RAVs became more fit (<xref ref-type="fig" rid="pcbi.1006335.g004">Fig 4C and 4D</xref>). Similarly, as <inline-formula id="pcbi.1006335.e041"><alternatives><graphic id="pcbi.1006335.e041g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e041" xlink:type="simple"/><mml:math display="inline" id="M41"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> decreased, failure occurred at lower <inline-formula id="pcbi.1006335.e042"><alternatives><graphic id="pcbi.1006335.e042g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e042" xlink:type="simple"/><mml:math display="inline" id="M42"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, indicating again that poorer IFN-responsiveness contributed to the failure of DAAs (<xref ref-type="fig" rid="pcbi.1006335.g004">Fig 4E and 4F</xref>). Further, as <italic>γ</italic><sub><italic>t</italic></sub> increased from &lt;&lt;1 to &gt;&gt;1, failure occurred first due to the wild-type, then the combination of wild-type and RAVs, and finally due to the RAVs alone (<xref ref-type="fig" rid="pcbi.1006335.g004">Fig 4G and 4H</xref>).</p>
<fig id="pcbi.1006335.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006335.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Response to PR+DAA treatment.</title>
<p><bold>(A)</bold> Phase diagram indicating regimes of IFN-responsiveness pre- and during treatment, <inline-formula id="pcbi.1006335.e043"><alternatives><graphic id="pcbi.1006335.e043g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e043" xlink:type="simple"/><mml:math display="inline" id="M43"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006335.e044"><alternatives><graphic id="pcbi.1006335.e044g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e044" xlink:type="simple"/><mml:math display="inline" id="M44"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, leading to SVR (dark blue) and treatment failure due to virological breakthrough by the RAV (light blue) for a fixed relative fitness of the RAV during treatment, <italic>γ</italic><sub><italic>t</italic></sub>. <bold>(B)</bold> Dynamics of wild-type (solid) and RAV (dashed) viral populations following treatment initiation for parameter combinations numbered in (A). <bold>(C)</bold> Phase diagram on a <inline-formula id="pcbi.1006335.e045"><alternatives><graphic id="pcbi.1006335.e045g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e045" xlink:type="simple"/><mml:math display="inline" id="M45"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> plot for fixed <inline-formula id="pcbi.1006335.e046"><alternatives><graphic id="pcbi.1006335.e046g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e046" xlink:type="simple"/><mml:math display="inline" id="M46"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. <bold>(D)</bold> Dynamics for the points numbered in (C). In (A)-(D), the DAA efficacy against the wild-type, <inline-formula id="pcbi.1006335.e047"><alternatives><graphic id="pcbi.1006335.e047g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e047" xlink:type="simple"/><mml:math display="inline" id="M47"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.99</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. Also, <italic>γ</italic> = 0.4. <bold>(E)-(H)</bold> Corresponding predictions with <inline-formula id="pcbi.1006335.e048"><alternatives><graphic id="pcbi.1006335.e048g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e048" xlink:type="simple"/><mml:math display="inline" id="M48"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.95</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. In (E) and (G), treatment failure occurred due to the RAV (light blue), wild-type (green), or both (brown). Here, <italic>γ</italic> = 0.2. Other parameter values employed are in <xref ref-type="supplementary-material" rid="pcbi.1006335.s008">S5 Table</xref>. Phase diagrams for other values of <inline-formula id="pcbi.1006335.e049"><alternatives><graphic id="pcbi.1006335.e049g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e049" xlink:type="simple"/><mml:math display="inline" id="M49"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> are in <xref ref-type="supplementary-material" rid="pcbi.1006335.s003">S3 Fig</xref>.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.g004" xlink:type="simple"/>
</fig>
<p>Thus, with DAA-based treatment, with or without PR, IFN-responsiveness controlled the growth of RAVs and contributed to treatment success. We examined next the implications of these findings at the population level. For this, we first estimated the distribution of IFN-responsiveness across individuals.</p>
</sec>
<sec id="sec008">
<title>Distribution of IFN-responsiveness in patient populations</title>
<p>We recognized that <inline-formula id="pcbi.1006335.e050"><alternatives><graphic id="pcbi.1006335.e050g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e050" xlink:type="simple"/><mml:math display="inline" id="M50"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> was linked directly to the chronic set-point viral load in our model (Methods; Eq. (S1.10)). The set-point viral load has been found to be log-normally distributed in chronically-infected individuals [<xref ref-type="bibr" rid="pcbi.1006335.ref044">44</xref>]. We therefore let <inline-formula id="pcbi.1006335.e051"><alternatives><graphic id="pcbi.1006335.e051g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e051" xlink:type="simple"/><mml:math display="inline" id="M51"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> also be log-normally distributed (Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e116">5</xref>); <xref ref-type="fig" rid="pcbi.1006335.g005">Fig 5A</xref>). Chronic infection was only possible in our model when <inline-formula id="pcbi.1006335.e052"><alternatives><graphic id="pcbi.1006335.e052g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e052" xlink:type="simple"/><mml:math display="inline" id="M52"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> was larger than a threshold, <inline-formula id="pcbi.1006335.e053"><alternatives><graphic id="pcbi.1006335.e053g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e053" xlink:type="simple"/><mml:math display="inline" id="M53"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. When <inline-formula id="pcbi.1006335.e054"><alternatives><graphic id="pcbi.1006335.e054g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e054" xlink:type="simple"/><mml:math display="inline" id="M54"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>≤</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, the set-point viral load was zero, marking spontaneous clearance of infection. Using representative model parameter values, we solved our model (Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>), Methods) using different values of <inline-formula id="pcbi.1006335.e055"><alternatives><graphic id="pcbi.1006335.e055g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e055" xlink:type="simple"/><mml:math display="inline" id="M55"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> and identified <inline-formula id="pcbi.1006335.e056"><alternatives><graphic id="pcbi.1006335.e056g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e056" xlink:type="simple"/><mml:math display="inline" id="M56"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> as the maximum value of <inline-formula id="pcbi.1006335.e057"><alternatives><graphic id="pcbi.1006335.e057g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e057" xlink:type="simple"/><mml:math display="inline" id="M57"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> for which the set-point viral load vanished. We thus obtained <inline-formula id="pcbi.1006335.e058"><alternatives><graphic id="pcbi.1006335.e058g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e058" xlink:type="simple"/><mml:math display="inline" id="M58"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.029</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. We next fit a truncated log-normal distribution for <inline-formula id="pcbi.1006335.e059"><alternatives><graphic id="pcbi.1006335.e059g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e059" xlink:type="simple"/><mml:math display="inline" id="M59"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>&gt;</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> (Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e121">6</xref>), <xref ref-type="fig" rid="pcbi.1006335.g005">Fig 5B</xref>) to patient data of the distribution of set-point viral load and identified parameter values defining the log-normal distribution of <inline-formula id="pcbi.1006335.e060"><alternatives><graphic id="pcbi.1006335.e060g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e060" xlink:type="simple"/><mml:math display="inline" id="M60"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> in a treatment-naïve population (<xref ref-type="fig" rid="pcbi.1006335.g005">Fig 5D</xref>, inset).</p>
<fig id="pcbi.1006335.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006335.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Distribution of IFN-responsiveness across patients and SVR rates to DAA-based treatments.</title>
<p><bold>(A)</bold> The log-normal probability density of the level of IFN-responsiveness, <inline-formula id="pcbi.1006335.e061"><alternatives><graphic id="pcbi.1006335.e061g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e061" xlink:type="simple"/><mml:math display="inline" id="M61"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, across individuals. The values of <inline-formula id="pcbi.1006335.e062"><alternatives><graphic id="pcbi.1006335.e062g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e062" xlink:type="simple"/><mml:math display="inline" id="M62"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> below which we observe spontaneous clearance, <inline-formula id="pcbi.1006335.e063"><alternatives><graphic id="pcbi.1006335.e063g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e063" xlink:type="simple"/><mml:math display="inline" id="M63"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, and below which the DAA would elicit SVR either alone, <inline-formula id="pcbi.1006335.e064"><alternatives><graphic id="pcbi.1006335.e064g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e064" xlink:type="simple"/><mml:math display="inline" id="M64"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, or with PR, <inline-formula id="pcbi.1006335.e065"><alternatives><graphic id="pcbi.1006335.e065g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e065" xlink:type="simple"/><mml:math display="inline" id="M65"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, are indicated. <inline-formula id="pcbi.1006335.e066"><alternatives><graphic id="pcbi.1006335.e066g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e066" xlink:type="simple"/><mml:math display="inline" id="M66"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> above which PR would elicit a null response, <italic>ϕ</italic><sub><italic>null</italic></sub>, is also indicated. The resulting probability density of <inline-formula id="pcbi.1006335.e067"><alternatives><graphic id="pcbi.1006335.e067g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e067" xlink:type="simple"/><mml:math display="inline" id="M67"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> in <bold>(B)</bold> treatment-naïve patients and <bold>(C)</bold> prior null responders to PR. <bold>(D)</bold> Comparisons of our model predictions (lines) of SVR rates in treatment-naive versus prior null responders to PR with corresponding observations from clinical trials involving IFN-free DAA regimens (open symbols) or PR+DAA combinations (filled symbols). Studies either distinguished individuals with (red) and without (blue) liver cirrhosis or not (black). The clinical data is collated in Tables <xref ref-type="table" rid="pcbi.1006335.t001">1</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006335.s004">S1</xref>. Model predictions (Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e137">13</xref>), Methods) with (orange) and without (green) PR overlap. The best-fit (black solid) along with 95% CI (black dashed) of Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e185">18</xref>) to the data where cirrhosis is not distinguished (collated in <xref ref-type="supplementary-material" rid="pcbi.1006335.s007">S4 Table</xref>) is shown. <italic>Inset</italic>: The log-normal probability density of <inline-formula id="pcbi.1006335.e068"><alternatives><graphic id="pcbi.1006335.e068g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e068" xlink:type="simple"/><mml:math display="inline" id="M68"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> in treatment-naïve individuals (line) fit to data of baseline viral loads from patients (symbols). The best-fit parameters were <italic>ν</italic> = −2.775 and <italic>σ</italic> = 1.027 (Methods).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.g005" xlink:type="simple"/>
</fig>
<p>With the resulting distribution, we estimated the percentage of individuals with <inline-formula id="pcbi.1006335.e069"><alternatives><graphic id="pcbi.1006335.e069g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e069" xlink:type="simple"/><mml:math display="inline" id="M69"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>≤</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> (Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e126">8</xref>)), <italic>i</italic>.<italic>e</italic>., the fraction of infected individuals who spontaneously clear the infection, and found it to be ~21%, close to the mean of ~26% obtained from 31 longitudinal studies [<xref ref-type="bibr" rid="pcbi.1006335.ref045">45</xref>].</p>
<p>We next considered null responders to PR, defined by <inline-formula id="pcbi.1006335.e070"><alternatives><graphic id="pcbi.1006335.e070g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e070" xlink:type="simple"/><mml:math display="inline" id="M70"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>. To estimate <italic>ϕ</italic><sub><italic>null</italic></sub>, we employed clinical data of telaprevir-based treatments. Using parameter values similar to previous estimates [<xref ref-type="bibr" rid="pcbi.1006335.ref012">12</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref046">46</xref>], <inline-formula id="pcbi.1006335.e071"><alternatives><graphic id="pcbi.1006335.e071g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e071" xlink:type="simple"/><mml:math display="inline" id="M71"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mo>≈</mml:mo><mml:mn>0.99</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pcbi.1006335.e072"><alternatives><graphic id="pcbi.1006335.e072g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e072" xlink:type="simple"/><mml:math display="inline" id="M72"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup><mml:mo>≈</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, and <italic>γ</italic> = 0.4, we applied our model (Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>)) and estimated <inline-formula id="pcbi.1006335.e073"><alternatives><graphic id="pcbi.1006335.e073g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e073" xlink:type="simple"/><mml:math display="inline" id="M73"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.065</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> as the value of <inline-formula id="pcbi.1006335.e074"><alternatives><graphic id="pcbi.1006335.e074g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e074" xlink:type="simple"/><mml:math display="inline" id="M74"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> below which telaprevir monotherapy would elicit SVR (Methods). (Note that telaprevir monotherapy can induce SVR [<xref ref-type="bibr" rid="pcbi.1006335.ref047">47</xref>].) We next estimated <inline-formula id="pcbi.1006335.e075"><alternatives><graphic id="pcbi.1006335.e075g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e075" xlink:type="simple"/><mml:math display="inline" id="M75"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, the value of <inline-formula id="pcbi.1006335.e076"><alternatives><graphic id="pcbi.1006335.e076g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e076" xlink:type="simple"/><mml:math display="inline" id="M76"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> below which PR+telaprevir triple therapy would yield SVR, by comparing model predictions of SVR rates in treatment-naïve patients (Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e130">9</xref>)) with corresponding clinical data [<xref ref-type="bibr" rid="pcbi.1006335.ref048">48</xref>], <inline-formula id="pcbi.1006335.e077"><alternatives><graphic id="pcbi.1006335.e077g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e077" xlink:type="simple"/><mml:math display="inline" id="M77"><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>75.4</mml:mn><mml:mo>±</mml:mo><mml:mn>2.4</mml:mn><mml:mi>%</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>. Given the distribution of <inline-formula id="pcbi.1006335.e078"><alternatives><graphic id="pcbi.1006335.e078g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e078" xlink:type="simple"/><mml:math display="inline" id="M78"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, the value of <inline-formula id="pcbi.1006335.e079"><alternatives><graphic id="pcbi.1006335.e079g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e079" xlink:type="simple"/><mml:math display="inline" id="M79"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> below which a defined percentage of the population lies can be calculated. Thus, the value of <inline-formula id="pcbi.1006335.e080"><alternatives><graphic id="pcbi.1006335.e080g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e080" xlink:type="simple"/><mml:math display="inline" id="M80"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> below which <inline-formula id="pcbi.1006335.e081"><alternatives><graphic id="pcbi.1006335.e081g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e081" xlink:type="simple"/><mml:math display="inline" id="M81"><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>75.4</mml:mn><mml:mo>±</mml:mo><mml:mn>2.4</mml:mn><mml:mi>%</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> of the population lies yielded <inline-formula id="pcbi.1006335.e082"><alternatives><graphic id="pcbi.1006335.e082g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e082" xlink:type="simple"/><mml:math display="inline" id="M82"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.152</mml:mn><mml:mo>±</mml:mo><mml:mn>0.011</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. This implied <inline-formula id="pcbi.1006335.e083"><alternatives><graphic id="pcbi.1006335.e083g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e083" xlink:type="simple"/><mml:math display="inline" id="M83"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi><mml:mo>=</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.087</mml:mn><mml:mo>±</mml:mo><mml:mn>0.011</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> was the increase in IFN-responsiveness due to exogenous IFN administered as part of PR treatment. With this Δ<italic>ϕ</italic>, we could estimate <inline-formula id="pcbi.1006335.e084"><alternatives><graphic id="pcbi.1006335.e084g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e084" xlink:type="simple"/><mml:math display="inline" id="M84"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> for any <inline-formula id="pcbi.1006335.e085"><alternatives><graphic id="pcbi.1006335.e085g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e085" xlink:type="simple"/><mml:math display="inline" id="M85"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, allowing us to use our model (Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>)) to predict the response to PR-containing regimens. In particular, we could predict the response to PR. Solving our model, we thus identified <italic>ϕ</italic><sub><italic>null</italic></sub> as the minimum <inline-formula id="pcbi.1006335.e086"><alternatives><graphic id="pcbi.1006335.e086g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e086" xlink:type="simple"/><mml:math display="inline" id="M86"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> that yielded a null response to PR, defined as having occurred when &lt;2 log<sub>10</sub> decline in viral load resulted from 12 weeks of treatment. We found that <italic>ϕ</italic><sub><italic>null</italic></sub> = 0.12±0.01 (Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>), Methods). Truncating the distribution of <inline-formula id="pcbi.1006335.e087"><alternatives><graphic id="pcbi.1006335.e087g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e087" xlink:type="simple"/><mml:math display="inline" id="M87"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> to values of <inline-formula id="pcbi.1006335.e088"><alternatives><graphic id="pcbi.1006335.e088g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e088" xlink:type="simple"/><mml:math display="inline" id="M88"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> above <italic>ϕ</italic><sub><italic>null</italic></sub> yielded the distribution of <inline-formula id="pcbi.1006335.e089"><alternatives><graphic id="pcbi.1006335.e089g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e089" xlink:type="simple"/><mml:math display="inline" id="M89"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> in null responders to PR (Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e124">7</xref>), <xref ref-type="fig" rid="pcbi.1006335.g005">Fig 5C</xref>).</p>
<p>With these estimates, we predicted the percentage of null responders to PR in a treatment-naïve population as the fraction of the population with <inline-formula id="pcbi.1006335.e090"><alternatives><graphic id="pcbi.1006335.e090g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e090" xlink:type="simple"/><mml:math display="inline" id="M90"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> above <italic>ϕ</italic><sub><italic>null</italic></sub> (Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e135">11</xref>)) and found <inline-formula id="pcbi.1006335.e091"><alternatives><graphic id="pcbi.1006335.e091g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e091" xlink:type="simple"/><mml:math display="inline" id="M91"><mml:mrow><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>33</mml:mn><mml:mi>%</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>, which was in close agreement with corresponding clinical observations of 32% [<xref ref-type="bibr" rid="pcbi.1006335.ref049">49</xref>]. Further, we predicted the response of null responders to PR+telaprevir triple therapy (Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e137">13</xref>)) as the fraction of null responders with <inline-formula id="pcbi.1006335.e092"><alternatives><graphic id="pcbi.1006335.e092g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e092" xlink:type="simple"/><mml:math display="inline" id="M92"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> below <inline-formula id="pcbi.1006335.e093"><alternatives><graphic id="pcbi.1006335.e093g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e093" xlink:type="simple"/><mml:math display="inline" id="M93"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> estimated above, and found <inline-formula id="pcbi.1006335.e094"><alternatives><graphic id="pcbi.1006335.e094g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e094" xlink:type="simple"/><mml:math display="inline" id="M94"><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>26</mml:mn><mml:mi>%</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>, again in good agreement with the 32% observed experimentally [<xref ref-type="bibr" rid="pcbi.1006335.ref048">48</xref>].</p>
<p>This quantitative agreement of our model with independent observations gave us confidence in our model and our estimates of the distribution of IFN-responsiveness. In addition, that the same Δ<italic>ϕ</italic> captured the observed influence of PR with and without telaprevir implied that the proposed synergy between IFN and DAAs [<xref ref-type="bibr" rid="pcbi.1006335.ref017">17</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref050">50</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref051">51</xref>] may be small in vivo. We next predicted the response of different patient subpopulations to DAA-based treatments.</p>
</sec>
<sec id="sec009">
<title>SVR rates elicited by DAA-based treatments</title>
<p>Using the distributions of IFN-responsiveness identified above, we applied our model (Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e137">13</xref>), Methods) to predict SVR rates elicited by DAA-based treatments. We varied parameters to mimic the entire spectrum of accessible DAA efficacies and relative fitness values of RAVs. We found that <italic>SVR</italic><sub><italic>null</italic></sub> was consistently lower than <italic>SVR</italic><sub><italic>naive</italic></sub> (<xref ref-type="fig" rid="pcbi.1006335.g005">Fig 5D</xref>). Further, our predictions were in good agreement with clinical data (<xref ref-type="fig" rid="pcbi.1006335.g005">Fig 5D</xref>; <xref ref-type="table" rid="pcbi.1006335.t001">Table 1</xref>). The predictions employed some parameters estimated above from telaprevir-based therapy. We derived an analytical expression linking <italic>SVR</italic><sub><italic>naive</italic></sub> and <italic>SVR</italic><sub><italic>null</italic></sub> that was independent of the DAA and of whether PR was part of the treatment (Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e185">18</xref>), Methods): <inline-formula id="pcbi.1006335.e095"><alternatives><graphic id="pcbi.1006335.e095g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e095" xlink:type="simple"/><mml:math display="inline" id="M95"><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow/></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. The expression too fit the clinical data well and the fit was close to our predictions above (<xref ref-type="fig" rid="pcbi.1006335.g005">Fig 5D</xref>). The best-fit estimate of <inline-formula id="pcbi.1006335.e096"><alternatives><graphic id="pcbi.1006335.e096g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e096" xlink:type="simple"/><mml:math display="inline" id="M96"><mml:mrow><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>40</mml:mn><mml:mo>±</mml:mo><mml:mn>14</mml:mn><mml:mi>%</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> was in agreement with the corresponding clinical estimate [<xref ref-type="bibr" rid="pcbi.1006335.ref049">49</xref>] of 32%. Further, the latter expression explained more vividly the diminishing difference between <italic>SVR</italic><sub><italic>naive</italic></sub> and <italic>SVR</italic><sub><italic>null</italic></sub> as treatment became more potent. It showed that when <italic>SVR</italic><sub><italic>naive</italic></sub> approached 100%, so did <italic>SVR</italic><sub><italic>null</italic></sub>, in agreement with observations from recent trials where nearly all patients were cured regardless of their treatment experience (<xref ref-type="table" rid="pcbi.1006335.t001">Table 1</xref>).</p>
<p>This agreement between our predictions, in two ways, and clinical data demonstrating <italic>SVR</italic><sub><italic>null</italic></sub> ≤ <italic>SVR</italic><sub><italic>naive</italic></sub> presents strong evidence supporting our hypothesis of the causal relationship between IFN-responsiveness and the success of DAA-based treatments. We examined ways of exploiting this relationship to improve treatments.</p>
</sec>
<sec id="sec010">
<title>Potential strategies to improve DAA-based treatments</title>
<p>IFN-responsiveness could be exploited to improve DAA-based treatments in two ways: 1) to prevent failure and 2) to shorten the treatment duration (<xref ref-type="fig" rid="pcbi.1006335.g006">Fig 6</xref>). IFN-free treatment would fail in an individual if <inline-formula id="pcbi.1006335.e097"><alternatives><graphic id="pcbi.1006335.e097g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e097" xlink:type="simple"/><mml:math display="inline" id="M97"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> in the individual were larger than a threshold. Adding PR would lower <inline-formula id="pcbi.1006335.e098"><alternatives><graphic id="pcbi.1006335.e098g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e098" xlink:type="simple"/><mml:math display="inline" id="M98"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> by Δ<italic>ϕ</italic>. Δ<italic>ϕ</italic> is expected to be different for individuals with (denoted Δ<italic>ϕ</italic><sub><italic>c</italic></sub>) and without (denoted Δ<italic>ϕ</italic><sub><italic>nc</italic></sub>) liver cirrhosis. We fit the analytical expression above (Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e185">18</xref>)) to SVR data on populations with and without liver cirrhosis separately (<xref ref-type="fig" rid="pcbi.1006335.g006">Fig 6A and 6B</xref>) and estimated Δ<italic>ϕ</italic><sub><italic>c</italic></sub> = 0.046 and Δ<italic>ϕ</italic><sub><italic>nc</italic></sub> = 0.091 (Methods). PR thus appeared only half as effective in improving IFN-responsiveness in cirrhotic individuals as non-cirrhotic individuals. Adding PR would thus induce SVR if the individual had a cirrhotic (non-cirrhotic) liver and the <inline-formula id="pcbi.1006335.e099"><alternatives><graphic id="pcbi.1006335.e099g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e099" xlink:type="simple"/><mml:math display="inline" id="M99"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> were within Δ<italic>ϕ</italic><sub><italic>c</italic></sub>(Δ<italic>ϕ</italic><sub><italic>nc</italic></sub>) of the threshold (<xref ref-type="fig" rid="pcbi.1006335.g006">Fig 6C, 6D, 6E and 6G</xref>). If <inline-formula id="pcbi.1006335.e100"><alternatives><graphic id="pcbi.1006335.e100g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e100" xlink:type="simple"/><mml:math display="inline" id="M100"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> were farther away from the threshold, adding PR alone would prove inadequate (<xref ref-type="fig" rid="pcbi.1006335.g006">Fig 6D, 6F and 6H</xref>). Increasing the DAA dosage or including additional DAAs to lower the effective fitness of the RAV may then be a way to induce SVR (<xref ref-type="fig" rid="pcbi.1006335.g006">Fig 6C–6G</xref>). Of course, adding PR may require a smaller increase in the DAA dosage, rendering the DAA more tolerable.</p>
<fig id="pcbi.1006335.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006335.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Strategies to overcome DAA failure.</title>
<p>The best-fit (solid line) and 95% CIs (dashed lines) of Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e185">18</xref>) (Methods) to data (symbols) of SVR rates in treatment-naïve versus treatment-experienced patients <bold>(A)</bold> without liver cirrhosis and <bold>(B)</bold> with liver cirrhosis, treated with DAAs with (filled) or without (open) PR. The list of clinical trials from which data has been collated is presented in <xref ref-type="supplementary-material" rid="pcbi.1006335.s005">S2</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006335.s006">S3</xref> Tables, respectively. The fits yielded <inline-formula id="pcbi.1006335.e101"><alternatives><graphic id="pcbi.1006335.e101g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e101" xlink:type="simple"/><mml:math display="inline" id="M101"><mml:mrow><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>58</mml:mn><mml:mo>±</mml:mo><mml:mn>10</mml:mn><mml:mi>%</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> and 33±14% in the two subpopulations, respectively, and using which, we estimated the corresponding <italic>ϕ</italic><sub><italic>null</italic></sub> = 0.07 and 0.12. <bold>(C)</bold> Regions in the phase diagram (see <xref ref-type="fig" rid="pcbi.1006335.g002">Fig 2A</xref>) where addition of PR to the DAA would elicit cure in otherwise failing patients with (orange) or without (orange and red) liver cirrhosis. SVR would be elicited in the dark blue region of the phase diagram. <bold>(D)</bold> The yellow box in (C) zoomed to demonstrate the influence of adding PR to an individual with a cirrhotic (small white arrow) or a non-cirrhotic (large white arrow) liver, adding a new DAA or increasing DAA dosage (yellow arrow), or adding PR and a new DAA (green arrow). <bold>(E-H)</bold> Dynamics of wild-type (solid) and RAV (dashed) viral populations following treatment initiation for the different conditions marked in (D). <bold>(I)</bold> The duration of treatment in weeks required to achieve SVR for a range of values of IFN-responsiveness, <inline-formula id="pcbi.1006335.e102"><alternatives><graphic id="pcbi.1006335.e102g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e102" xlink:type="simple"/><mml:math display="inline" id="M102"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, and the relative fitness of the RAV, <italic>γ</italic><sub><italic>t</italic></sub>. <bold>(J)</bold> Dynamics of wild-type (solid) and RAV (dashed) viral populations following treatment initiation for the different conditions marked in (I), corresponding to daclatasvir treatment (Methods). <italic>Inset</italic>: The percentage of patients predicted to achieve SVR as a function of the duration of treatment with daclatasvir. The percentages corresponding to the conditions marked in (I) are indicated. Thus, 19.2%, 46% and 60.6% SVR rates are expected in 8, 10, and 12 weeks of treatment, respectively.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.g006" xlink:type="simple"/>
</fig>
<p>Even where DAA-based treatment is likely to succeed, greater IFN-responsiveness would induce faster viral load decline and allow shorter treatment durations (<xref ref-type="fig" rid="pcbi.1006335.g006">Fig 6I and 6J</xref>). Using parameters representative of daclatasvir (Methods), we found that as <inline-formula id="pcbi.1006335.e103"><alternatives><graphic id="pcbi.1006335.e103g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e103" xlink:type="simple"/><mml:math display="inline" id="M103"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> decreased from ~0.1 to ~0.04, the treatment duration required for SVR dropped from ~12 weeks to ~8 weeks (<xref ref-type="fig" rid="pcbi.1006335.g006">Fig 6I and 6J</xref>). Although daclatasvir is not recommended for use as monotherapy, we use it here for illustration and because the NS5A region, the target of daclatasvir, is the one region where resistance testing may decide the choice of regimen [<xref ref-type="bibr" rid="pcbi.1006335.ref003">3</xref>]. Thus, individuals highly responsive to IFN present promising candidates for reducing DAA treatment durations. Indeed, we estimated that ~50% of the individuals treated with daclatasvir would achieve SVR in ~10 weeks and ~20% in ~8 weeks, durations expected to decrease further with DAA combinations, presenting a basis and a novel avenue for response-guided treatment.</p>
</sec>
</sec>
<sec id="sec011" sec-type="conclusions">
<title>Discussion</title>
<p>DAAs, with &gt;90% SVR rates in clinical trials, are bringing hope to the millions of chronically HCV infected individuals worldwide. In the present study, we elucidated a hypothesis underlying the unexpected positive correlation between the response elicited by DAAs and PR, which explains several confounding clinical observations and presents new potential avenues to improve DAA-based treatments. The hypothesis is that greater IFN-responsiveness restricts the replication space available for the virus, inhibiting the development of resistance to DAAs and improving treatment response. We developed a novel multiscale mathematical model to test this hypothesis. Analysis of a large body of clinical data using the model presented evidence in strong support of the hypothesis. The resulting causal relationship between responsiveness to PR and DAAs implied that increased responsiveness to PR could be exploited to prevent DAA failure and/or shorten the treatment duration, potentially positively impacting treatment response, tolerability, affordability and access.</p>
<p>Despite the high SVR rates they elicit, access to DAA-based treatments has seen limited so far; &lt;1.3% of the ~150 million chronically HCV infected individuals are estimated to have received DAA-based treatment, with the proportion far smaller in resource-limited settings [<xref ref-type="bibr" rid="pcbi.1006335.ref052">52</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref053">53</xref>]. To improve affordability and access, DAA-based treatments that would exert the most potent antiviral activity and/or patient subpopulations that would require the shortest durations are keenly being sought [<xref ref-type="bibr" rid="pcbi.1006335.ref054">54</xref>–<xref ref-type="bibr" rid="pcbi.1006335.ref059">59</xref>]. Our study informs these efforts by presenting new avenues to optimize DAA-based treatments. The standard strategy to avert DAA failure is to increase the genetic barrier to resistance by including more DAAs in the drug cocktail [<xref ref-type="bibr" rid="pcbi.1006335.ref012">12</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref054">54</xref>]. In a recent set of studies, for instance, numerous DAA combinations were evaluated preclinically to identify the “best” candidates for clinical development and 3 DAA combinations were found to be more potent than 2 DAA combinations [<xref ref-type="bibr" rid="pcbi.1006335.ref054">54</xref>–<xref ref-type="bibr" rid="pcbi.1006335.ref056">56</xref>]. We suggest that an alternative strategy may often be feasible: improving IFN-responsiveness by adding IFN (or PR). Where additional DAAs remain inaccessible, especially in resource-limited settings, such a strategy may be useful. A previous modeling study also found that the efficacy of combining PR with a DAA significantly improved the treatment efficacy against DAA-resistant strains compared to the DAA alone [<xref ref-type="bibr" rid="pcbi.1006335.ref012">12</xref>]. Furthermore, our study quantified the gain in IFN-responsiveness due to standard PR dosage in patients with and without liver cirrhosis, representing a key potential step in personalizing the strategy. Response-guided treatment (RGT) is being considered now to define reduced treatment durations for select populations [<xref ref-type="bibr" rid="pcbi.1006335.ref027">27</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref057">57</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref058">58</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref060">60</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref061">61</xref>]. For instance, in a recent study, patients who achieved an ultra-rapid early viral load decline (plasma HCV RNA &lt;500 copies/mL by day 2) were found to be cured with just 3 weeks of treatment [<xref ref-type="bibr" rid="pcbi.1006335.ref057">57</xref>]. Our prediction that individuals with high IFN-responsiveness are amenable to shorter treatment durations presents a much sought-after basis and a promising candidate population for reducing treatment durations, informing ongoing efforts to develop RGT protocols.</p>
<p>Personalizing treatment based on the avenues above requires estimation of the level of IFN-responsiveness of individuals. For a treatment-experienced individual, this may be achieved through analysis of viral load changes recorded during the previous PR treatment [<xref ref-type="bibr" rid="pcbi.1006335.ref017">17</xref>]. For a treatment-naive individual, short-term PR exposure and subsequent measurements of viral load may be necessary. Viral load changes as early as 24 h following the start of PR treatment have been argued to be good indicators of eventual response [<xref ref-type="bibr" rid="pcbi.1006335.ref062">62</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref063">63</xref>]. Previous modeling studies have suggested a lead-in period of PR to assess the level of ongoing viral replication and the responsiveness to PR in order to decide optimal treatments [<xref ref-type="bibr" rid="pcbi.1006335.ref012">12</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref064">64</xref>]. Developing such indicators to quantify the level of IFN-responsiveness, a promising future research direction based on our present study, would allow personalizing the course of DAA treatments also for treatment-naive individuals. Further, a correlation between IFN-responsiveness and the duration of DAA-based treatment required to achieve SVR would present a direct clinical test of our hypothesis.</p>
<p>Recent studies present further evidence in support of our hypothesis. In a study involving 240 chronic HCV patients treated with sofosbuvir and either daclatasvir or simeprevir for 12 weeks, slow responders, defined as those with detectable viremia at week 12, had a much higher representation of treatment (PR)-experienced patients than the overall population, <italic>viz</italic>., 82% versus 68%, indicating that IFN-free DAA treatments elicited slower viral load declines in individuals with poorer IFN-responsiveness [<xref ref-type="bibr" rid="pcbi.1006335.ref065">65</xref>]. Another study involving 216 patients treated with sofosbuvir and either daclatasvir or ledipasvir for 12 weeks found that baseline RAVs and treatment experience did not influence SVR in patients without cirrhosis but had a significant influence in patients with cirrhosis [<xref ref-type="bibr" rid="pcbi.1006335.ref066">66</xref>]. In yet another study [<xref ref-type="bibr" rid="pcbi.1006335.ref013">13</xref>], 6 of the 8 patients treated with daclatasvir and PR achieved SVR, of which 4 had RAVs detected pre-treatment, but had favourable IL28B genotypes (TT/GT) [<xref ref-type="bibr" rid="pcbi.1006335.ref037">37</xref>] and were treatment-naive or partial responders to prior IFN therapy. The 2 who failed treatment had unfavorable/partially favorable IL28B genotypes (GG/GT) and were null responders to prior IFN therapy. They experienced virological breakthrough due to the growth of RAVs although the RAVs were not detected pre-treatment. Earlier studies with the first generation DAAs provide further evidence. In a pooled study involving a large number of patients treated with boceprevir and PR, SVR rates were 78% and 76% in IFN-responders with and without baseline RAVs, respectively, whereas in poor IFN-responders, the corresponding SVR rates were 22% and 37% [<xref ref-type="bibr" rid="pcbi.1006335.ref067">67</xref>]. Similarly, with telaprevir, on-treatment virological failure rates were 1% in previous relapsers to PR, 19% in previous partial responders to PR, and 52% in previous null responders to PR [<xref ref-type="bibr" rid="pcbi.1006335.ref068">68</xref>]. Thus, in all the above cases, treatment failure was due to drug resistance, which did not depend on the pre-existence of RAVs but was facilitated by poor IFN-responsiveness. Conversely, strong IFN responses appeared to prevent the growth of RAVs and avert treatment failure. These findings are consistent with our model predictions.</p>
<p>Our study makes key advances in our understanding of HCV infection and treatment. To test the hypothesized causal relationship between responsiveness to IFN and DAAs, we had to construct a model that integrated phenomena across multiple length and time scales, starting from the cellular to the population level. Responsiveness to IFN manifests at the cellular level, defining the fraction of cells that can be rid of HCV by IFN. The consequence at the level of an infected individual is in restricting viral replication and evolution and hence improving responsiveness to DAAs. At the population level, this effect, given the distribution of IFN-responsiveness, determines SVR rates. Integration of phenomena across these scales into a single mathematical framework had not been accomplished thus far. Our model, by doing so, was able to capture the implications of variations at the cellular level, due to drugs, for instance, for the population-level treatment response. This allowed us to describe many clinical observations of which several had long remained unexplained, <italic>viz</italic>., 1) the percentage of infected individuals who spontaneously clear HCV, 2) the percentage of chronically infected individuals who exhibit a null response to PR, 3) the percentage of null responders to PR who respond to triple therapy with PR and a DAA such as telaprevir, and 4) the relationship between SVR rates in treatment-naive and treatment-experienced patients elicited by different treatments. A far more comprehensive view of HCV infection and treatment than earlier thus emerges.</p>
<p>The model we developed is complex. Yet, we only considered phenomena essential to establishing the causal relationship between IFN-responsiveness and DAA-based treatment outcomes. We thus ignored alternative mechanisms of DAA action [<xref ref-type="bibr" rid="pcbi.1006335.ref023">23</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref069">69</xref>], specific intracellular viral replication events [<xref ref-type="bibr" rid="pcbi.1006335.ref011">11</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref024">24</xref>], modes of synergy between IFN and DAAs [<xref ref-type="bibr" rid="pcbi.1006335.ref017">17</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref051">51</xref>], and factors such as race, gender, viral genotype, and IL28B polymorphisms [<xref ref-type="bibr" rid="pcbi.1006335.ref001">1</xref>]. Furthermore, we did not estimate the IFN-responsiveness of an individual <italic>a priori</italic>. The key components of the IFN signaling network in cells have been identified [<xref ref-type="bibr" rid="pcbi.1006335.ref028">28</xref>], but variations in their levels and interactions across cells in an individual, which would determine the fraction of cells responsive to IFN, remain to be established. Finally, we assumed SVR to have been achieved when the viral load dropped below the “cure boundary” of 1 virion in the ~15 liters of fluid volume in an individual [<xref ref-type="bibr" rid="pcbi.1006335.ref005">5</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref016">16</xref>]. With the new DAA combinations, some individuals with detectable viremia at the end of treatment have been found recently to achieve SVR [<xref ref-type="bibr" rid="pcbi.1006335.ref070">70</xref>]. The origins of this intriguing phenomenon, which may lead to the definition of a new cure boundary, remain poorly elucidated [<xref ref-type="bibr" rid="pcbi.1006335.ref071">71</xref>–<xref ref-type="bibr" rid="pcbi.1006335.ref073">73</xref>]. By employing the “stricter” cure boundary, our model yields conservative estimates of SVR rates.</p>
</sec>
<sec id="sec012" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec013">
<title>Mathematical model</title>
<sec id="sec014">
<title>IFN-responsiveness and viral kinetics in an individual undergoing DAA-based treatment</title>
<p>We considered an individual chronically infected with HCV, subjected to a DAA-based treatment regimen. We constructed the following equations to describe the viral kinetics in the individual following the start of treatment when a single point mutation was adequate to confer resistance to the DAA:
<disp-formula id="pcbi.1006335.e104">
<alternatives>
<graphic id="pcbi.1006335.e104g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e104" xlink:type="simple"/>
<mml:math display="block" id="M104">
<mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:msub><mml:mi>T</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mn>3</mml:mn></mml:munderover><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mn>1</mml:mn></mml:munderover><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:mstyle></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:mstyle></mml:mrow><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi mathvariant="normal">max</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mn>1</mml:mn></mml:munderover><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:msub><mml:mi>V</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:msub><mml:mi>T</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>;</mml:mo><mml:mspace width="3em"/><mml:mi>i</mml:mi><mml:mo>∈</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">}</mml:mo></mml:mrow>
</mml:math>
</alternatives>
<label>(1)</label>
</disp-formula>
<disp-formula id="pcbi.1006335.e105">
<alternatives>
<graphic id="pcbi.1006335.e105g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e105" xlink:type="simple"/>
<mml:math display="block" id="M105">
<mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mi>I</mml:mi></mml:msub><mml:msubsup><mml:mi>I</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mn>3</mml:mn></mml:munderover><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mn>1</mml:mn></mml:munderover><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:msubsup></mml:mrow></mml:mstyle></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:mstyle></mml:mrow><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi mathvariant="normal">max</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:msub><mml:mi>V</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mi>δ</mml:mi><mml:msubsup><mml:mi>I</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup><mml:mo>;</mml:mo><mml:mspace width="3em"/><mml:mi>i</mml:mi><mml:mo>∈</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">}</mml:mo><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>∈</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">}</mml:mo></mml:mrow>
</mml:math>
</alternatives>
<label>(2)</label>
</disp-formula>
<disp-formula id="pcbi.1006335.e106">
<alternatives>
<graphic id="pcbi.1006335.e106g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e106" xlink:type="simple"/>
<mml:math display="block" id="M106">
<mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>V</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>μ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mn>3</mml:mn></mml:munderover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:mstyle><mml:mo>−</mml:mo><mml:mi>c</mml:mi><mml:msub><mml:mi>V</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow>
</mml:math>
</alternatives>
<label>(3)</label>
</disp-formula>
<disp-formula id="pcbi.1006335.e107">
<alternatives>
<graphic id="pcbi.1006335.e107g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e107" xlink:type="simple"/>
<mml:math display="block" id="M107">
<mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>V</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>μ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mn>3</mml:mn></mml:munderover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:mstyle><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mn>3</mml:mn></mml:munderover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msubsup><mml:mi>I</mml:mi><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:msubsup></mml:mrow></mml:mstyle><mml:mo>−</mml:mo><mml:mi>c</mml:mi><mml:msub><mml:mi>V</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow>
</mml:math>
</alternatives>
<label>(4)</label>
</disp-formula></p>
<p>Here, we classified uninfected target cells into 3 categories, denoted <italic>T</italic><sub><italic>i</italic></sub> with <italic>i</italic>ϵ{1,2,3}, based on the properties of the IFN signalling network in cells we identified earlier [<xref ref-type="bibr" rid="pcbi.1006335.ref017">17</xref>] (see <xref ref-type="sec" rid="sec002">Results</xref>). Broadly, IFN induces the expression of ISGs that suppress HCV, whereas HCV subverts the IFN response by blocking ISG translation. The resulting network, with the double negative feedback, exhibits bistability, <italic>i</italic>.<italic>e</italic>., two stable steady states, with HCV thriving in one and cleared by IFN in the other. The steady states define the 3 cell categories based on their IFN response phenotypes. Cells <italic>T</italic><sub>1</sub> admitted the first steady state alone and were refractory to IFN. IFN would prevent neither the infection of <italic>T</italic><sub>1</sub> nor viral production from them following their infection. Cells <italic>T</italic><sub>2</sub> admitted both the steady states and were bistable. Such cells are driven to the IFN-refractory state following their infection if the HCV RNA level crosses a threshold before exposure to IFN [<xref ref-type="bibr" rid="pcbi.1006335.ref017">17</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref030">30</xref>]. Else, they are driven to the IFN-responsive state. Thus, as an approximation, we assumed that IFN would prevent infection of <italic>T</italic><sub>2</sub> if they were exposed to IFN before the virus, but fail to prevent viral production from such cells once infected. Cells <italic>T</italic><sub>3</sub> admitted the second steady state alone and were sensitive to IFN. IFN would thus prevent infection of <italic>T</italic><sub>3</sub> and if infected block viral production from such cells.</p>
<p><italic>s</italic> was the production rate of target cells, and <italic>ϕ</italic><sub><italic>i</italic></sub> was the fraction of the cells produced that was of type <italic>T</italic><sub><italic>i</italic></sub>. In the absence of infection and when cell proliferation is small, <italic>ϕ</italic><sub><italic>i</italic></sub> equals the fraction of the target cells that is of type <italic>T</italic><sub><italic>i</italic></sub>. <italic>ϕ</italic><sub>1</sub> was thus the fraction of cells refractory to IFN and quantified the level of IFN-responsiveness of an individual. Lower values of <italic>ϕ</italic><sub>1</sub> represented greater IFN-responsiveness. We set <inline-formula id="pcbi.1006335.e108"><alternatives><graphic id="pcbi.1006335.e108g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e108" xlink:type="simple"/><mml:math display="inline" id="M108"><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> pre-treatment and during IFN-free treatment and <inline-formula id="pcbi.1006335.e109"><alternatives><graphic id="pcbi.1006335.e109g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e109" xlink:type="simple"/><mml:math display="inline" id="M109"><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> during IFN-containing treatment. The cells died with the rate constant <italic>d</italic><sub><italic>T</italic></sub>. The cells were also lost due to infection by free virions.</p>
<p><italic>V</italic><sub>0</sub> and <italic>V</italic><sub>1</sub> were the wild-type and RAV viral populations, respectively. When a cell <italic>T</italic><sub><italic>i</italic></sub> was infected by a virion <italic>V</italic><sub><italic>j</italic></sub>, it gave rise to an infected cell of the type <inline-formula id="pcbi.1006335.e110"><alternatives><graphic id="pcbi.1006335.e110g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e110" xlink:type="simple"/><mml:math display="inline" id="M110"><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. The infectivity of the virions <italic>V</italic><sub><italic>j</italic></sub> was denoted <italic>β</italic><sub><italic>j</italic></sub>. Further, successful infection of the cell <italic>T</italic><sub><italic>i</italic></sub> was blocked by IFN with efficacy <italic>η</italic><sub><italic>i</italic></sub>. From the description above, it followed that <italic>η</italic><sub>1</sub> = 0 and <italic>η</italic><sub>2</sub> = <italic>η</italic><sub>3</sub> = 1. Target cells and infected cells proliferated with rate constants <italic>r</italic><sub><italic>T</italic></sub> and <italic>r</italic><sub><italic>I</italic></sub>, respectively, constrained by a logistic term with carrying capacity <italic>T</italic><sub>max</sub>. <italic>N</italic> represented the population of target cells not susceptible to infection, due, for instance, to the lack of adequate entry receptors [<xref ref-type="bibr" rid="pcbi.1006335.ref074">74</xref>]. Infected cells were lost with the rate constant <italic>δ</italic>.</p>
<p><italic>p</italic><sub><italic>j</italic></sub> represented the per cell production rate of virions from cells <inline-formula id="pcbi.1006335.e111"><alternatives><graphic id="pcbi.1006335.e111g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e111" xlink:type="simple"/><mml:math display="inline" id="M111"><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. IFN constrained this production with effectiveness <italic>ε</italic><sub><italic>i</italic></sub>, dependent on the cell phenotype. Again, from the description above, <italic>ε</italic><sub>1</sub> = <italic>ε</italic><sub>2</sub> = 0 and <italic>ε</italic><sub>3</sub> = 1.</p>
<p>DAAs limited viral production from all cells with effectiveness <inline-formula id="pcbi.1006335.e112"><alternatives><graphic id="pcbi.1006335.e112g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e112" xlink:type="simple"/><mml:math display="inline" id="M112"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, dependent on the viral variant. Mutations arose randomly and compromised DAA activity. The mutations came with a fitness cost to the virus, determined here by lower values of <italic>β</italic><sub><italic>j</italic></sub> and/or <italic>p</italic><sub><italic>j</italic></sub>. Specifically, mutation at the rate <italic>μ</italic> allowed the production of <italic>V</italic><sub>1</sub> from cells <inline-formula id="pcbi.1006335.e113"><alternatives><graphic id="pcbi.1006335.e113g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e113" xlink:type="simple"/><mml:math display="inline" id="M113"><mml:mrow><mml:msubsup><mml:mi>I</mml:mi><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, infected with <italic>V</italic><sub>0</sub>. We ignored back mutation of <italic>V</italic><sub>1</sub> to <italic>V</italic><sub>0</sub> (e.g., see [<xref ref-type="bibr" rid="pcbi.1006335.ref012">12</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref022">22</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref075">75</xref>]). Free virions were cleared with the rate constant <italic>c</italic>.</p>
<p>A generalization of the formalism to multiple resistance loci is presented in <xref ref-type="supplementary-material" rid="pcbi.1006335.s010">S2 Text</xref>.</p>
</sec>
<sec id="sec015">
<title>Distribution of IFN-responsiveness across treatment-naive and -experienced individuals</title>
<p>We assumed that <inline-formula id="pcbi.1006335.e114"><alternatives><graphic id="pcbi.1006335.e114g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e114" xlink:type="simple"/><mml:math display="inline" id="M114"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> was log-normally distributed with parameters <italic>ν</italic> and <italic>σ</italic> across individuals in a treatment-naive HCV-infected population. The density function for <inline-formula id="pcbi.1006335.e115"><alternatives><graphic id="pcbi.1006335.e115g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e115" xlink:type="simple"/><mml:math display="inline" id="M115"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> was thus
<disp-formula id="pcbi.1006335.e116">
<alternatives>
<graphic id="pcbi.1006335.e116g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e116" xlink:type="simple"/>
<mml:math display="block" id="M116">
<mml:mrow><mml:mi>f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mi>A</mml:mi><mml:mrow><mml:msqrt><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi></mml:mrow></mml:msqrt><mml:mi>σ</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:mfrac><mml:mi mathvariant="normal">exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">ln</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>−</mml:mo><mml:mi>ν</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>;</mml:mo><mml:mspace width="2em"/><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>≤</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo></mml:mrow>
</mml:math>
</alternatives>
<label>(5)</label>
</disp-formula>
where <inline-formula id="pcbi.1006335.e117"><alternatives><graphic id="pcbi.1006335.e117g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e117" xlink:type="simple"/><mml:math display="inline" id="M117"><mml:mrow><mml:mi>A</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mn>0</mml:mn><mml:mn>1</mml:mn></mml:munderover><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msqrt><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi></mml:mrow></mml:msqrt><mml:mi>σ</mml:mi><mml:mi>ϕ</mml:mi></mml:mrow></mml:mfrac><mml:mi mathvariant="normal">exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">ln</mml:mi><mml:mi>ϕ</mml:mi><mml:mo>−</mml:mo><mml:mi>ν</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mrow></mml:mstyle><mml:mi>ϕ</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> ensured that <inline-formula id="pcbi.1006335.e118"><alternatives><graphic id="pcbi.1006335.e118g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e118" xlink:type="simple"/><mml:math display="inline" id="M118"><mml:mrow><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mn>0</mml:mn><mml:mn>1</mml:mn></mml:munderover><mml:mrow><mml:mi>f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mrow></mml:mstyle><mml:mi>ϕ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>.</p>
<p>When <inline-formula id="pcbi.1006335.e119"><alternatives><graphic id="pcbi.1006335.e119g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e119" xlink:type="simple"/><mml:math display="inline" id="M119"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup><mml:mo>≈</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mi>c</mml:mi><mml:mi>δ</mml:mi><mml:mo>/</mml:mo><mml:mi>β</mml:mi><mml:mi>s</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> (Eq. (S1.10)), the model above (Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>)) resulted in vanishing set-point viral load pre-treatment, potentially representing individuals who spontaneously clear HCV [<xref ref-type="bibr" rid="pcbi.1006335.ref017">17</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref045">45</xref>]. The distribution of <inline-formula id="pcbi.1006335.e120"><alternatives><graphic id="pcbi.1006335.e120g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e120" xlink:type="simple"/><mml:math display="inline" id="M120"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> in chronically infected, treatment-naive individuals thus became the truncated log-normal,
<disp-formula id="pcbi.1006335.e121">
<alternatives>
<graphic id="pcbi.1006335.e121g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e121" xlink:type="simple"/>
<mml:math display="block" id="M121">
<mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow><mml:mn>1</mml:mn></mml:munderover><mml:mrow><mml:mi>f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:mrow></mml:mstyle><mml:mi>ϕ</mml:mi></mml:mrow></mml:mfrac><mml:mo>;</mml:mo><mml:mspace width="3em"/><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>≤</mml:mo><mml:mn>1</mml:mn><mml:mo>.</mml:mo></mml:mrow>
</mml:math>
</alternatives>
<label>(6)</label>
</disp-formula></p>
<p>We denoted by <italic>ϕ</italic><sub><italic>null</italic></sub> the value of <inline-formula id="pcbi.1006335.e122"><alternatives><graphic id="pcbi.1006335.e122g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e122" xlink:type="simple"/><mml:math display="inline" id="M122"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> above which PR treatment elicited a null response. Null response, or non-response, was defined as having occurred when &lt;2 log<sub>10</sub> decline in viral load resulted from 12 weeks of treatment. Given <italic>ϕ</italic><sub><italic>null</italic></sub>, the density function of <inline-formula id="pcbi.1006335.e123"><alternatives><graphic id="pcbi.1006335.e123g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e123" xlink:type="simple"/><mml:math display="inline" id="M123"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> in null responders,
<disp-formula id="pcbi.1006335.e124">
<alternatives>
<graphic id="pcbi.1006335.e124g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e124" xlink:type="simple"/>
<mml:math display="block" id="M124">
<mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mn>1</mml:mn></mml:munderover><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>ϕ</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mi>d</mml:mi><mml:mi>ϕ</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mfrac><mml:mo>;</mml:mo><mml:mspace width="3em"/><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>≤</mml:mo><mml:mn>1</mml:mn><mml:mo>.</mml:mo></mml:mrow>
</mml:math>
</alternatives>
<label>(7)</label>
</disp-formula></p>
</sec>
<sec id="sec016">
<title>Rates of spontaneous clearance, null response, and SVR in populations</title>
<p>The fraction, <italic>CL</italic>, of HCV infected individuals who spontaneously clear the infection would include all those with <inline-formula id="pcbi.1006335.e125"><alternatives><graphic id="pcbi.1006335.e125g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e125" xlink:type="simple"/><mml:math display="inline" id="M125"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>; i.e.,
<disp-formula id="pcbi.1006335.e126">
<alternatives>
<graphic id="pcbi.1006335.e126g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e126" xlink:type="simple"/>
<mml:math display="block" id="M126">
<mml:mrow><mml:mi>C</mml:mi><mml:mi>L</mml:mi><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow></mml:munderover><mml:mrow><mml:mi>f</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle><mml:mi>d</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>.</mml:mo></mml:mrow>
</mml:math>
</alternatives>
<label>(8)</label>
</disp-formula></p>
<p>We defined <inline-formula id="pcbi.1006335.e127"><alternatives><graphic id="pcbi.1006335.e127g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e127" xlink:type="simple"/><mml:math display="inline" id="M127"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> as the highest value of <inline-formula id="pcbi.1006335.e128"><alternatives><graphic id="pcbi.1006335.e128g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e128" xlink:type="simple"/><mml:math display="inline" id="M128"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> for which a treatment-naive individual would achieve SVR when subjected to a particular IFN-free DAA regimen. SVR was defined as achieved when the viral load reached a value &lt;1 virion in the 15 liters of fluid volume in an individual by the end of treatment [<xref ref-type="bibr" rid="pcbi.1006335.ref005">5</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref016">16</xref>]. The fraction of the population treated with the regimen that would achieve SVR, which we called <inline-formula id="pcbi.1006335.e129"><alternatives><graphic id="pcbi.1006335.e129g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e129" xlink:type="simple"/><mml:math display="inline" id="M129"><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, would therefore be
<disp-formula id="pcbi.1006335.e130">
<alternatives>
<graphic id="pcbi.1006335.e130g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e130" xlink:type="simple"/>
<mml:math display="block" id="M130">
<mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle><mml:mi>d</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>.</mml:mo></mml:mrow>
</mml:math>
</alternatives>
<label>(9)</label>
</disp-formula></p>
<p>Similarly, if <inline-formula id="pcbi.1006335.e131"><alternatives><graphic id="pcbi.1006335.e131g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e131" xlink:type="simple"/><mml:math display="inline" id="M131"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> was the highest value of <inline-formula id="pcbi.1006335.e132"><alternatives><graphic id="pcbi.1006335.e132g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e132" xlink:type="simple"/><mml:math display="inline" id="M132"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> for which SVR was achieved with the above DAA regimen combined with PR, the fraction of a treatment-naive population that would achieve SVR with this combination would be
<disp-formula id="pcbi.1006335.e133">
<alternatives>
<graphic id="pcbi.1006335.e133g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e133" xlink:type="simple"/>
<mml:math display="block" id="M133">
<mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle><mml:mi>d</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>.</mml:mo></mml:mrow>
</mml:math>
</alternatives>
<label>(10)</label>
</disp-formula>
The fraction of a treatment-naive population that would exhibit a null response to PR, denoted <inline-formula id="pcbi.1006335.e134"><alternatives><graphic id="pcbi.1006335.e134g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e134" xlink:type="simple"/><mml:math display="inline" id="M134"><mml:mrow><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, would be
<disp-formula id="pcbi.1006335.e135">
<alternatives>
<graphic id="pcbi.1006335.e135g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e135" xlink:type="simple"/>
<mml:math display="block" id="M135">
<mml:mrow><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mn>1</mml:mn></mml:munderover><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle><mml:mi>d</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>.</mml:mo></mml:mrow>
</mml:math>
</alternatives>
<label>(11)</label>
</disp-formula>
Of the prior null responders to PR, the fraction that would respond to the above DAA would be
<disp-formula id="pcbi.1006335.e136">
<alternatives>
<graphic id="pcbi.1006335.e136g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e136" xlink:type="simple"/>
<mml:math display="block" id="M136">
<mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle><mml:mi>d</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow>
</mml:math>
</alternatives>
<label>(12)</label>
</disp-formula>
and, finally, to the PR+DAA combination would be
<disp-formula id="pcbi.1006335.e137">
<alternatives>
<graphic id="pcbi.1006335.e137g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e137" xlink:type="simple"/>
<mml:math display="block" id="M137">
<mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle><mml:mi>d</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>.</mml:mo></mml:mrow>
</mml:math>
</alternatives>
<label>(13)</label>
</disp-formula></p>
</sec>
<sec id="sec017">
<title>The distributions and threshold values of <inline-formula id="pcbi.1006335.e138"><alternatives><graphic id="pcbi.1006335.e138g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e138" xlink:type="simple"/><mml:math display="inline" id="M138"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> and the linkage between individual- and population-level models</title>
<p>We identified the various threshold values of <inline-formula id="pcbi.1006335.e139"><alternatives><graphic id="pcbi.1006335.e139g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e139" xlink:type="simple"/><mml:math display="inline" id="M139"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> mentioned above as follows. We first solved our viral dynamics model (Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>)) using parameter values listed in <xref ref-type="supplementary-material" rid="pcbi.1006335.s008">S5 Table</xref> and identified <inline-formula id="pcbi.1006335.e140"><alternatives><graphic id="pcbi.1006335.e140g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e140" xlink:type="simple"/><mml:math display="inline" id="M140"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. Next, we recognized that the baseline viral load when <inline-formula id="pcbi.1006335.e141"><alternatives><graphic id="pcbi.1006335.e141g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e141" xlink:type="simple"/><mml:math display="inline" id="M141"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>&gt;</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> is <inline-formula id="pcbi.1006335.e142"><alternatives><graphic id="pcbi.1006335.e142g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e142" xlink:type="simple"/><mml:math display="inline" id="M142"><mml:mrow><mml:mi>V</mml:mi><mml:mo>≈</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mi>s</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>δ</mml:mi></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo>≈</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mi>s</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>δ</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></inline-formula> (see Eq. (S1.10) in <xref ref-type="supplementary-material" rid="pcbi.1006335.s009">S1 Text</xref> and the parameter estimates in <xref ref-type="supplementary-material" rid="pcbi.1006335.s008">S5 Table</xref>), which has the maximum, <inline-formula id="pcbi.1006335.e143"><alternatives><graphic id="pcbi.1006335.e143g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e143" xlink:type="simple"/><mml:math display="inline" id="M143"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="normal">max</mml:mi></mml:mrow></mml:msub><mml:mo>≈</mml:mo><mml:mfrac><mml:mrow><mml:mi>s</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>δ</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></inline-formula> when <inline-formula id="pcbi.1006335.e144"><alternatives><graphic id="pcbi.1006335.e144g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e144" xlink:type="simple"/><mml:math display="inline" id="M144"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. It followed that <inline-formula id="pcbi.1006335.e145"><alternatives><graphic id="pcbi.1006335.e145g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e145" xlink:type="simple"/><mml:math display="inline" id="M145"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>≈</mml:mo><mml:mi>V</mml:mi><mml:mo>/</mml:mo><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="normal">max</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>. We therefore fit Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e121">6</xref>) to the reported distribution of <italic>V</italic>/<italic>V</italic><sub>max</sub> values [<xref ref-type="bibr" rid="pcbi.1006335.ref044">44</xref>] and obtained <italic>ν</italic> and <italic>σ</italic>.</p>
<p>For any DAA, <inline-formula id="pcbi.1006335.e146"><alternatives><graphic id="pcbi.1006335.e146g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e146" xlink:type="simple"/><mml:math display="inline" id="M146"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> can be estimated by solving Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>) for different values of <inline-formula id="pcbi.1006335.e147"><alternatives><graphic id="pcbi.1006335.e147g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e147" xlink:type="simple"/><mml:math display="inline" id="M147"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> and with <inline-formula id="pcbi.1006335.e148"><alternatives><graphic id="pcbi.1006335.e148g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e148" xlink:type="simple"/><mml:math display="inline" id="M148"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> corresponding to the effectiveness of the DAA against wild-type and RAV strains, and identifying the maximum value of <inline-formula id="pcbi.1006335.e149"><alternatives><graphic id="pcbi.1006335.e149g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e149" xlink:type="simple"/><mml:math display="inline" id="M149"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> for which SVR is achieved. For IFN-containing regimens, Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>) cannot be solved to obtain <inline-formula id="pcbi.1006335.e150"><alternatives><graphic id="pcbi.1006335.e150g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e150" xlink:type="simple"/><mml:math display="inline" id="M150"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> because the relationship between <inline-formula id="pcbi.1006335.e151"><alternatives><graphic id="pcbi.1006335.e151g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e151" xlink:type="simple"/><mml:math display="inline" id="M151"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> when <inline-formula id="pcbi.1006335.e152"><alternatives><graphic id="pcbi.1006335.e152g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e152" xlink:type="simple"/><mml:math display="inline" id="M152"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> is not known <italic>a priori</italic>. We therefore employed population-level observations of <inline-formula id="pcbi.1006335.e153"><alternatives><graphic id="pcbi.1006335.e153g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e153" xlink:type="simple"/><mml:math display="inline" id="M153"><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> for telaprevir [<xref ref-type="bibr" rid="pcbi.1006335.ref048">48</xref>] and solved Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e126">8</xref>) for <inline-formula id="pcbi.1006335.e154"><alternatives><graphic id="pcbi.1006335.e154g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e154" xlink:type="simple"/><mml:math display="inline" id="M154"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. This yielded an estimate of <inline-formula id="pcbi.1006335.e155"><alternatives><graphic id="pcbi.1006335.e155g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e155" xlink:type="simple"/><mml:math display="inline" id="M155"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi><mml:mo>=</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> for telaprevir. Because the dynamics during treatment is dictated essentially by <inline-formula id="pcbi.1006335.e156"><alternatives><graphic id="pcbi.1006335.e156g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e156" xlink:type="simple"/><mml:math display="inline" id="M156"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> (see <xref ref-type="sec" rid="sec002">Results</xref>), it followed that <inline-formula id="pcbi.1006335.e157"><alternatives><graphic id="pcbi.1006335.e157g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e157" xlink:type="simple"/><mml:math display="inline" id="M157"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup><mml:mo>≈</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> when <inline-formula id="pcbi.1006335.e158"><alternatives><graphic id="pcbi.1006335.e158g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e158" xlink:type="simple"/><mml:math display="inline" id="M158"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, defining the threshold for SVR. Δ<italic>ϕ</italic> is therefore a measure of the increase in IFN-responsiveness due to the addition of IFN as part of PR treatment. Further, because synergy between telaprevir and PR appears small (see <xref ref-type="sec" rid="sec002">Results</xref>), Δ<italic>ϕ</italic> represents the increase in IFN-responsiveness brought about independently by PR.</p>
<p>We validated the resulting estimate of Δ<italic>ϕ</italic> as follows. Δ<italic>ϕ</italic> would depend on the extent of increase in the IFN concentration above the endogenous level because of treatment. For standard PR dosage, Δ<italic>ϕ</italic> may thus be assumed to apply across individuals. (We recognized that this assumption would fail when <inline-formula id="pcbi.1006335.e159"><alternatives><graphic id="pcbi.1006335.e159g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e159" xlink:type="simple"/><mml:math display="inline" id="M159"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> is small and where the influence of IFN is expected to saturate. A small <inline-formula id="pcbi.1006335.e160"><alternatives><graphic id="pcbi.1006335.e160g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e160" xlink:type="simple"/><mml:math display="inline" id="M160"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, however, would amount to an already IFN-sensitive individual and to whom addition of PR is likely to be unnecessary.) Δ<italic>ϕ</italic> may differ between individuals with cirrhotic and non-cirrhotic livers, which we address below. Using the above estimate of Δ<italic>ϕ</italic>, we solved Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>) for different values of <inline-formula id="pcbi.1006335.e161"><alternatives><graphic id="pcbi.1006335.e161g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e161" xlink:type="simple"/><mml:math display="inline" id="M161"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006335.e162"><alternatives><graphic id="pcbi.1006335.e162g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e162" xlink:type="simple"/><mml:math display="inline" id="M162"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>−</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> and identified <italic>ϕ</italic><sub><italic>null</italic></sub> as the lowest <inline-formula id="pcbi.1006335.e163"><alternatives><graphic id="pcbi.1006335.e163g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e163" xlink:type="simple"/><mml:math display="inline" id="M163"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> that yielded a null response. With the resulting value of <italic>ϕ</italic><sub><italic>null</italic></sub>, we estimated <inline-formula id="pcbi.1006335.e164"><alternatives><graphic id="pcbi.1006335.e164g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e164" xlink:type="simple"/><mml:math display="inline" id="M164"><mml:mrow><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> using Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e135">11</xref>) and <inline-formula id="pcbi.1006335.e165"><alternatives><graphic id="pcbi.1006335.e165g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e165" xlink:type="simple"/><mml:math display="inline" id="M165"><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> using Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e137">13</xref>) and compared the estimates with observations [<xref ref-type="bibr" rid="pcbi.1006335.ref048">48</xref>, <xref ref-type="bibr" rid="pcbi.1006335.ref049">49</xref>].</p>
<p>With the distributions and all the threshold values of <inline-formula id="pcbi.1006335.e166"><alternatives><graphic id="pcbi.1006335.e166g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e166" xlink:type="simple"/><mml:math display="inline" id="M166"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> thus identified, Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e137">13</xref>) presented a model that could predict the outcomes of DAA-based treatments at the individual and the population level.</p>
</sec>
</sec>
<sec id="sec018">
<title>Solution of model equations</title>
<sec id="sec019">
<title>Viral kinetics</title>
<p>In our model, DAAs are distinguished by their efficacies, <inline-formula id="pcbi.1006335.e167"><alternatives><graphic id="pcbi.1006335.e167g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e167" xlink:type="simple"/><mml:math display="inline" id="M167"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, against sensitive and resistant strains as well as the relative fitness of the respective RAVs, defined by <italic>γ</italic>. To describe the scenario pre-treatment in different individuals, we set <inline-formula id="pcbi.1006335.e168"><alternatives><graphic id="pcbi.1006335.e168g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e168" xlink:type="simple"/><mml:math display="inline" id="M168"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> and solved Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>) for steady state to obtain the set point viral load and the frequencies and populations of RAVs as functions of <inline-formula id="pcbi.1006335.e169"><alternatives><graphic id="pcbi.1006335.e169g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e169" xlink:type="simple"/><mml:math display="inline" id="M169"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. We also derived analytical approximations of these steady state quantities (<xref ref-type="supplementary-material" rid="pcbi.1006335.s009">S1 Text</xref>). Using the above steady state as the initial condition, we solved Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>) with <inline-formula id="pcbi.1006335.e170"><alternatives><graphic id="pcbi.1006335.e170g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e170" xlink:type="simple"/><mml:math display="inline" id="M170"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msubsup><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006335.e171"><alternatives><graphic id="pcbi.1006335.e171g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e171" xlink:type="simple"/><mml:math display="inline" id="M171"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> to describe viral load changes following the onset of IFN-free DAA-based treatment. For IFN-containing regimens, we followed the same procedure but with <inline-formula id="pcbi.1006335.e172"><alternatives><graphic id="pcbi.1006335.e172g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e172" xlink:type="simple"/><mml:math display="inline" id="M172"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>.</p>
</sec>
<sec id="sec020">
<title>Parameter estimates and sensitivity</title>
<p>Model equations were solved using parameter values representative of HCV infection <italic>in vivo</italic>, listed in <xref ref-type="supplementary-material" rid="pcbi.1006335.s008">S5 Table</xref>. Sensitivity of model predictions to parameter values was tested by computing the partial rank correlation coefficients (PRCC) [<xref ref-type="bibr" rid="pcbi.1006335.ref076">76</xref>].</p>
</sec>
<sec id="sec021">
<title>SVR rates</title>
<p>For given values of <inline-formula id="pcbi.1006335.e173"><alternatives><graphic id="pcbi.1006335.e173g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e173" xlink:type="simple"/><mml:math display="inline" id="M173"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> and <italic>γ</italic>, representing a particular DAA or DAA combination, Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e137">13</xref>) were solved to obtain estimates of SVR rates in treatment-naïve and treatment-experienced patients. The values of <inline-formula id="pcbi.1006335.e174"><alternatives><graphic id="pcbi.1006335.e174g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e174" xlink:type="simple"/><mml:math display="inline" id="M174"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mi>j</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> and <italic>γ</italic> have not been characterized for most DAAs. <italic>γ</italic> and the ratio <inline-formula id="pcbi.1006335.e175"><alternatives><graphic id="pcbi.1006335.e175g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e175" xlink:type="simple"/><mml:math display="inline" id="M175"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, however, must lie between 0 and 1 for all DAAs. We therefore varied each of these quantities over the entire range of values from 0 to 1 and computed SVR rates, where each combination of these parameter values would represent a different DAA-based treatment. For each combination, we first estimated <inline-formula id="pcbi.1006335.e176"><alternatives><graphic id="pcbi.1006335.e176g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e176" xlink:type="simple"/><mml:math display="inline" id="M176"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> by solving Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>). Next, using Δ<italic>ϕ</italic> obtained above, we estimated <inline-formula id="pcbi.1006335.e177"><alternatives><graphic id="pcbi.1006335.e177g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e177" xlink:type="simple"/><mml:math display="inline" id="M177"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>. All the other model parameters and quantities remained independent of the DAAs. Using Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e116">5</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e137">13</xref>), we estimated SVRs in treatment-naïve and treatment-experienced individuals. Repeating this with other parameter combinations yielded a relationship between SVR rates in the two patient populations, which we compared with clinical data. We also derived an analytical expression for the latter relationship below.</p>
<p>The numerical solutions were implemented in MATLAB.</p>
</sec>
</sec>
<sec id="sec022">
<title>Relationship between SVR rates in treatment-naïve and treatment-experienced patients</title>
<p>We let <italic>SVR</italic><sub><italic>naive</italic></sub> and <italic>SVR</italic><sub><italic>null</italic></sub> be the response to any given DAA-based treatment in a treatment-naïve and a previous null responder population, respectively. We derived an analytical expression linking <italic>SVR</italic><sub><italic>naive</italic></sub> and <italic>SVR</italic><sub><italic>null</italic></sub> as follows. From our model above, it followed that
<disp-formula id="pcbi.1006335.e178">
<alternatives>
<graphic id="pcbi.1006335.e178g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e178" xlink:type="simple"/>
<mml:math display="block" id="M178">
<mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow/></mml:msubsup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow/></mml:msubsup></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle><mml:mi>d</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow>
</mml:math>
</alternatives>
<label>(14)</label>
</disp-formula>
and
<disp-formula id="pcbi.1006335.e179">
<alternatives>
<graphic id="pcbi.1006335.e179g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e179" xlink:type="simple"/>
<mml:math display="block" id="M179">
<mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow/></mml:msubsup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow/></mml:msubsup></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle><mml:mi>d</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>.</mml:mo></mml:mrow>
</mml:math>
</alternatives>
<label>(15)</label>
</disp-formula>
Using the relationship between <inline-formula id="pcbi.1006335.e180"><alternatives><graphic id="pcbi.1006335.e180g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e180" xlink:type="simple"/><mml:math display="inline" id="M180"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006335.e181"><alternatives><graphic id="pcbi.1006335.e181g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e181" xlink:type="simple"/><mml:math display="inline" id="M181"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula> (Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e124">7</xref>)) in Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e179">15</xref>) yielded
<disp-formula id="pcbi.1006335.e182">
<alternatives>
<graphic id="pcbi.1006335.e182g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e182" xlink:type="simple"/>
<mml:math display="block" id="M182">
<mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow/></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow/></mml:msubsup></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle><mml:mi>d</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mn>1</mml:mn></mml:munderover><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow/></mml:msubsup></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle><mml:mi>d</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow>
</mml:math>
</alternatives>
<label>(16)</label>
</disp-formula>
where <inline-formula id="pcbi.1006335.e183"><alternatives><graphic id="pcbi.1006335.e183g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e183" xlink:type="simple"/><mml:math display="inline" id="M183"><mml:mrow><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> is defined in Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e135">11</xref>). We next rearranged the integral in Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e182">16</xref>) as
<disp-formula id="pcbi.1006335.e184">
<alternatives>
<graphic id="pcbi.1006335.e184g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e184" xlink:type="simple"/>
<mml:math display="block" id="M184">
<mml:mrow><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow/></mml:msubsup></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle><mml:mi>d</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle><mml:mi>d</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow/></mml:msubsup></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mstyle><mml:mi>d</mml:mi><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow>
</mml:math>
</alternatives>
<label>(17)</label>
</disp-formula>
and obtained upon combining with Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e182">16</xref>) and rearranging,
<disp-formula id="pcbi.1006335.e185">
<alternatives>
<graphic id="pcbi.1006335.e185g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e185" xlink:type="simple"/>
<mml:math display="block" id="M185">
<mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:msubsup><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow/></mml:msubsup><mml:mo>.</mml:mo></mml:mrow>
</mml:math>
</alternatives>
<label>(18)</label>
</disp-formula></p>
<p>We fit the expression above to clinical data using the NLINFIT algorithm in MATLAB.</p>
</sec>
<sec id="sec023">
<title>Data from clinical trials</title>
<p>We examined reports of all clinical trials with DAA-based treatments and considered those treatments for which SVR data on both treatment-naïve and treatment-experienced individuals was available. The resulting data is summarized in <xref ref-type="table" rid="pcbi.1006335.t001">Table 1</xref> and <xref ref-type="supplementary-material" rid="pcbi.1006335.s004">S1 Table</xref>. We also classified the patient populations into categories with and without liver cirrhosis. We performed statistical tests to ascertain the difference in the SVR rates between treatment-naïve and treatment-experienced individuals for specific treatments as well as when data for all the treatments considered were combined. We compared the predictions above of SVR rates with the data from clinical trials.</p>
</sec>
<sec id="sec024">
<title>IFN-responsiveness of cirrhotic and non-cirrhotic patients</title>
<p>Next, we considered SVR data on patients with and without liver cirrhosis separately. Predicting this data using our model was not possible because Δ<italic>ϕ</italic> and <italic>ϕ</italic><sub><italic>null</italic></sub> in these populations were not known. We therefore fit Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e185">18</xref>) to the two data sets separately using <inline-formula id="pcbi.1006335.e186"><alternatives><graphic id="pcbi.1006335.e186g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e186" xlink:type="simple"/><mml:math display="inline" id="M186"><mml:mrow><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> as an adjustable parameter. The distribution of baseline viral loads is not hugely different between the two populations, although mean viral loads were somewhat smaller in patients with liver cirrhosis [<xref ref-type="bibr" rid="pcbi.1006335.ref044">44</xref>]. Using Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e135">11</xref>) and the best-fit estimates of <inline-formula id="pcbi.1006335.e187"><alternatives><graphic id="pcbi.1006335.e187g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e187" xlink:type="simple"/><mml:math display="inline" id="M187"><mml:mrow><mml:mi>N</mml:mi><mml:mi>U</mml:mi><mml:mi>L</mml:mi><mml:msubsup><mml:mi>L</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, we obtained estimates of <italic>ϕ</italic><sub><italic>null</italic></sub> in the two populations. Finally, we solved our model of viral dynamics (Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>)) with <inline-formula id="pcbi.1006335.e188"><alternatives><graphic id="pcbi.1006335.e188g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e188" xlink:type="simple"/><mml:math display="inline" id="M188"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> for different values of <inline-formula id="pcbi.1006335.e189"><alternatives><graphic id="pcbi.1006335.e189g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e189" xlink:type="simple"/><mml:math display="inline" id="M189"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>−</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi></mml:mrow></mml:math></alternatives></inline-formula> and identified the highest value of <inline-formula id="pcbi.1006335.e190"><alternatives><graphic id="pcbi.1006335.e190g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e190" xlink:type="simple"/><mml:math display="inline" id="M190"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> that yielded a null response. The resulting values of <inline-formula id="pcbi.1006335.e191"><alternatives><graphic id="pcbi.1006335.e191g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e191" xlink:type="simple"/><mml:math display="inline" id="M191"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ϕ</mml:mi><mml:mo>=</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> provided estimates of the extent of increase in IFN-responsiveness due to standard PR treatment in cirrhotic and non-cirrhotic patients, respectively, which allowed recommendation of strategies to improve treatments in these subpopulations.</p>
</sec>
<sec id="sec025">
<title>Estimation of required treatment duration</title>
<p>Finally, we calculated the required duration of treatment to achieve SVR for different <inline-formula id="pcbi.1006335.e192"><alternatives><graphic id="pcbi.1006335.e192g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e192" xlink:type="simple"/><mml:math display="inline" id="M192"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> and <italic>γ</italic><sub><italic>t</italic></sub>. We chose parameters representative of daclatasvir as follows. The EC<sub>50</sub> of daclatasvir against the wild-type [<xref ref-type="bibr" rid="pcbi.1006335.ref077">77</xref>] and the RAV [<xref ref-type="bibr" rid="pcbi.1006335.ref078">78</xref>] were 17.28 pM and 32346.26 pM, respectively. (The molecular weight of daclatasvir is 738.89 g/mol.) Using the pharmacokinetic parameters of daclatasvir [<xref ref-type="bibr" rid="pcbi.1006335.ref079">79</xref>], the peak and trough plasma concentrations, <italic>C</italic><sub>max</sub> = 1726.4 ng/ml and <italic>C</italic><sub>min</sub> = 254.6 ng/ml, the dosing interval of 1 d, and the time to reach peak plasma concentration of 1 h, we calculated the average efficacy of daclatasvir against the wild-type and the RAV, following the procedure outlined earlier [<xref ref-type="bibr" rid="pcbi.1006335.ref077">77</xref>], to be 0.99998 and 0.709, respectively. With these values, we solved our model of viral dynamics (Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>)) for different values of <inline-formula id="pcbi.1006335.e193"><alternatives><graphic id="pcbi.1006335.e193g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e193" xlink:type="simple"/><mml:math display="inline" id="M193"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> and the intrinsic fitness of the RAV, <italic>γ</italic>, and estimated the duration of treatment required to achieve SVR. For the common RAV Y93H, <italic>γ</italic> = 0.5751 [<xref ref-type="bibr" rid="pcbi.1006335.ref077">77</xref>]. Using this value of <italic>γ</italic> and the distribution of <inline-formula id="pcbi.1006335.e194"><alternatives><graphic id="pcbi.1006335.e194g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e194" xlink:type="simple"/><mml:math display="inline" id="M194"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> in treatment naïve individuals (Eq (<xref ref-type="disp-formula" rid="pcbi.1006335.e121">6</xref>)), we estimated the fraction of individuals treated who would achieve SVR within a defined treatment duration.</p>
</sec>
</sec>
<sec id="sec026">
<title>Supporting information</title>
<supplementary-material id="pcbi.1006335.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.s001" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Sensitivity analysis of the viral kinetic model.</title>
<p>Partial rank correlation coefficients (PRCCs) indicating the sensitivity of our model predictions (Eqs (<xref ref-type="disp-formula" rid="pcbi.1006335.e104">1</xref>)–(<xref ref-type="disp-formula" rid="pcbi.1006335.e107">4</xref>) and (S2.1)-(S2.4)) of <bold>(A)</bold> single mutant population pre-treatment, <bold>(B)</bold> single mutant population during DAA treatment, <bold>(C)</bold> double mutant population pre-treatment, and <bold>(D)</bold> double mutant population during DAA treatment to variations in model parameter values. The model is considered sensitive to parameters with PRCCs significantly different from the dummy. Thus, the model is sensitive to <inline-formula id="pcbi.1006335.e195"><alternatives><graphic id="pcbi.1006335.e195g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e195" xlink:type="simple"/><mml:math display="inline" id="M195"><mml:mrow><mml:mi>μ</mml:mi><mml:mo>,</mml:mo><mml:mi>γ</mml:mi><mml:mo>,</mml:mo><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi>c</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives></inline-formula> and <italic>δ</italic> pre-treatment, in agreement with the parameters defining the mutant population in the analytical approximation in Eq. (S1.11), and additionally to the drug efficacies, <inline-formula id="pcbi.1006335.e196"><alternatives><graphic id="pcbi.1006335.e196g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e196" xlink:type="simple"/><mml:math display="inline" id="M196"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006335.e197"><alternatives><graphic id="pcbi.1006335.e197g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e197" xlink:type="simple"/><mml:math display="inline" id="M197"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, during treatment. For these calculations, we adapted the MATLAB codes available on Dr. Denise Kirschner’s website (<ext-link ext-link-type="uri" xlink:href="http://malthus.micro.med.umich.edu/lab/usadata" xlink:type="simple">http://malthus.micro.med.umich.edu/lab/usadata</ext-link>).</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006335.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.s002" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>Phase diagrams indicating response to IFN-free DAA treatments.</title>
<p>The level of IFN-refractoriness, <inline-formula id="pcbi.1006335.e198"><alternatives><graphic id="pcbi.1006335.e198g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e198" xlink:type="simple"/><mml:math display="inline" id="M198"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, and the relative fitness of the RAV during treatment, <italic>γ</italic><sub><italic>t</italic></sub>, that lead to SVR (dark blue) or treatment failure due to virological breakthrough by the RAV (light blue), wild-type (green), or both (brown) when <bold>(A)</bold> <inline-formula id="pcbi.1006335.e199"><alternatives><graphic id="pcbi.1006335.e199g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e199" xlink:type="simple"/><mml:math display="inline" id="M199"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>0</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.70</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, <bold>(B)</bold> <inline-formula id="pcbi.1006335.e200"><alternatives><graphic id="pcbi.1006335.e200g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e200" xlink:type="simple"/><mml:math display="inline" id="M200"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>0</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.80</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, <bold>(C)</bold> <inline-formula id="pcbi.1006335.e201"><alternatives><graphic id="pcbi.1006335.e201g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e201" xlink:type="simple"/><mml:math display="inline" id="M201"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>0</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.90</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>, <bold>(D)</bold> <inline-formula id="pcbi.1006335.e202"><alternatives><graphic id="pcbi.1006335.e202g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e202" xlink:type="simple"/><mml:math display="inline" id="M202"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>0</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.99</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. Here, <italic>γ</italic> = 0.5. The other parameters are the same as in <xref ref-type="fig" rid="pcbi.1006335.g003">Fig 3</xref>.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006335.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.s003" xlink:type="simple">
<label>S3 Fig</label>
<caption>
<title>Phase diagrams indicating response to PR+DAA treatments.</title>
<p>IFN-refractoriness pre- and during treatment, <inline-formula id="pcbi.1006335.e203"><alternatives><graphic id="pcbi.1006335.e203g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e203" xlink:type="simple"/><mml:math display="inline" id="M203"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>p</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006335.e204"><alternatives><graphic id="pcbi.1006335.e204g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e204" xlink:type="simple"/><mml:math display="inline" id="M204"><mml:mrow><mml:msubsup><mml:mi>ϕ</mml:mi><mml:mn>1</mml:mn><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula>, leading to SVR (dark blue), or virological breakthrough by RAV (light blue), wild-type (green), or both (brown) when <bold>(A)</bold> <inline-formula id="pcbi.1006335.e205"><alternatives><graphic id="pcbi.1006335.e205g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e205" xlink:type="simple"/><mml:math display="inline" id="M205"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>0</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.99</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>; <bold>(B)</bold> <inline-formula id="pcbi.1006335.e206"><alternatives><graphic id="pcbi.1006335.e206g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e206" xlink:type="simple"/><mml:math display="inline" id="M206"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>0</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.99</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>; <bold>(C)</bold> <inline-formula id="pcbi.1006335.e207"><alternatives><graphic id="pcbi.1006335.e207g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e207" xlink:type="simple"/><mml:math display="inline" id="M207"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>0</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.99</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.3</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>; <bold>(D)</bold> <inline-formula id="pcbi.1006335.e208"><alternatives><graphic id="pcbi.1006335.e208g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e208" xlink:type="simple"/><mml:math display="inline" id="M208"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>0</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.95</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>; <bold>(E)</bold> <inline-formula id="pcbi.1006335.e209"><alternatives><graphic id="pcbi.1006335.e209g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e209" xlink:type="simple"/><mml:math display="inline" id="M209"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>0</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.95</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> and <bold>(F)</bold> <inline-formula id="pcbi.1006335.e210"><alternatives><graphic id="pcbi.1006335.e210g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006335.e210" xlink:type="simple"/><mml:math display="inline" id="M210"><mml:mrow><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>0</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.95</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>ε</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.3</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. Here, <italic>γ</italic> = 0.1. The other parameters are the same as in <xref ref-type="fig" rid="pcbi.1006335.g004">Fig 4</xref>.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006335.s004" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.s004" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Response to DAA-based treatments.</title>
<p>SVR rates elicited by various IFN-free and IFN-containing DAA combinations in treatment-naïve and prior null responders to PR from recent clinical trials. The treated population size is indicated in brackets. The significance of the difference in the SVR rates in the two populations is computed using the χ<sup>2</sup> and the Fisher’s exact tests. The HCV genotype and whether the patients had liver cirrhosis is indicated. Data from all trials involving a particular treatment regimen are combined for the statistical analysis.</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006335.s005" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.s005" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Response to DAA-based treatments in patients with liver cirrhosis.</title>
<p>The datasets in <xref ref-type="supplementary-material" rid="pcbi.1006335.s004">S1 Table</xref> that consider patients with liver cirrhosis alone are summarized.</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006335.s006" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.s006" xlink:type="simple">
<label>S3 Table</label>
<caption>
<title>Response to DAA-based treatments in patients without liver cirrhosis.</title>
<p>The datasets in <xref ref-type="supplementary-material" rid="pcbi.1006335.s004">S1 Table</xref> that consider patients without liver cirrhosis alone are summarized.</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006335.s007" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.s007" xlink:type="simple">
<label>S4 Table</label>
<caption>
<title>Response to DAA-based treatments from studies that do not distinguish between patients with and without cirrhosis.</title>
<p>The datasets in <xref ref-type="supplementary-material" rid="pcbi.1006335.s004">S1 Table</xref> that consider patients without distinction in cirrhosis are summarized.</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006335.s008" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.s008" xlink:type="simple">
<label>S5 Table</label>
<caption>
<title>Model parameters.</title>
<p>Definitions of model parameters and their typical values employed. Variations are mentioned in the text.</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006335.s009" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.s009" xlink:type="simple">
<label>S1 Text</label>
<caption>
<title>Analytical approximation of the pre-treatment steady state with a single resistance locus.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006335.s010" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.s010" xlink:type="simple">
<label>S2 Text</label>
<caption>
<title>Model formulation with multiple resistance loci.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1006335.s011" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006335.s011" xlink:type="simple">
<label>S3 Text</label>
<caption>
<title>Analytical approximation of the pre-treatment steady state with two or more resistance loci.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pcbi.1006335.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Horner</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Naggie</surname> <given-names>S</given-names></name>. <article-title>Successes and challenges on the road to cure hepatitis C</article-title>. <source>PLoS Pathog</source>. <year>2015</year>;<volume>11</volume>:<fpage>e1004854</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1004854" xlink:type="simple">10.1371/journal.ppat.1004854</ext-link></comment> <object-id pub-id-type="pmid">26087286</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref002"><label>2</label><mixed-citation publication-type="book" xlink:type="simple"><collab>WHO</collab>. <source>Guidelines for the screening care and treatment of persons with chronic hepatitis C infection</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2016</year>.</mixed-citation></ref>
<ref id="pcbi.1006335.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><article-title>EASL recommendations on treatment of hepatitis C 2016</article-title>. <source>J Hepatol</source>. <year>2017</year>;<volume>66</volume>:<fpage>153</fpage>–<lpage>194</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jhep.2016.09.001" xlink:type="simple">10.1016/j.jhep.2016.09.001</ext-link></comment> <object-id pub-id-type="pmid">27667367</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heim</surname> <given-names>MH</given-names></name>. <article-title>Innate immunity and HCV</article-title>. <source>J Hepatol</source>. <year>2013</year>;<volume>58</volume>:<fpage>564</fpage>–<lpage>574</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jhep.2012.10.005" xlink:type="simple">10.1016/j.jhep.2012.10.005</ext-link></comment> <object-id pub-id-type="pmid">23063572</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dixit</surname> <given-names>NM</given-names></name>, <name name-style="western"><surname>Layden-Almer</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Layden</surname> <given-names>TJ</given-names></name>, <name name-style="western"><surname>Perelson</surname> <given-names>AS</given-names></name>. <article-title>Modelling how ribavirin improves interferon response rates in hepatitis C virus infection</article-title>. <source>Nature</source>. <year>2004</year>;<volume>432</volume>:<fpage>922</fpage>–<lpage>924</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature03153" xlink:type="simple">10.1038/nature03153</ext-link></comment> <object-id pub-id-type="pmid">15602565</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rotman</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Noureddin</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Feld</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Guedj</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Witthaus</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Han</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C</article-title>. <source>Gut</source>. <year>2014</year>;<volume>63</volume>:<fpage>161</fpage>–<lpage>169</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/gutjnl-2012-303852" xlink:type="simple">10.1136/gutjnl-2012-303852</ext-link></comment> <object-id pub-id-type="pmid">23396509</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gotte</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Feld</surname> <given-names>JJ</given-names></name>. <article-title>Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. <year>2016</year>;<volume>13</volume>:<fpage>338</fpage>–<lpage>351</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrgastro.2016.60" xlink:type="simple">10.1038/nrgastro.2016.60</ext-link></comment> <object-id pub-id-type="pmid">27147491</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lontok</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Harrington</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Howe</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kieffer</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Lennerstrand</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lenz</surname> <given-names>O</given-names></name>, <etal>et al</etal>. <article-title>Hepatitis C virus drug resistance–associated substitutions: State of the art summary</article-title>. <source>Hepatology</source>. <year>2015</year>;<volume>62</volume>:<fpage>1623</fpage>–<lpage>1632</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/hep.27934" xlink:type="simple">10.1002/hep.27934</ext-link></comment> <object-id pub-id-type="pmid">26095927</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ahmed</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Felmlee</surname> <given-names>D</given-names></name>. <article-title>Mechanisms of hepatitis c viral resistance to direct acting antivirals</article-title>. <source>Viruses</source>. <year>2015</year>;<volume>7</volume>:<fpage>2968</fpage>.</mixed-citation></ref>
<ref id="pcbi.1006335.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Neumann</surname> <given-names>AU</given-names></name>, <name name-style="western"><surname>Lam</surname> <given-names>NP</given-names></name>, <name name-style="western"><surname>Dahari</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Gretch</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Wiley</surname> <given-names>TE</given-names></name>, <name name-style="western"><surname>Layden</surname> <given-names>TJ</given-names></name>, <etal>et al</etal>. <article-title>Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy</article-title>. <source>Science</source>. <year>1998</year>;<volume>282</volume>:<fpage>103</fpage>–<lpage>107</lpage>. <object-id pub-id-type="pmid">9756471</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ribeiro</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Stoddard</surname> <given-names>MB</given-names></name>, <name name-style="western"><surname>Learn</surname> <given-names>GH</given-names></name>, <name name-style="western"><surname>Korber</surname> <given-names>BT</given-names></name>, <etal>et al</etal>. <article-title>Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate</article-title>. <source>PLoS Pathog</source>. <year>2012</year>;<volume>8</volume>:<fpage>e1002881</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1002881" xlink:type="simple">10.1371/journal.ppat.1002881</ext-link></comment> <object-id pub-id-type="pmid">22927817</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rong</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Dahari</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ribeiro</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Perelson</surname> <given-names>AS</given-names></name>. <article-title>Rapid emergence of protease inhibitor resistance in hepatitis C virus</article-title>. <source>Sci Transl Med</source>. <year>2010</year>;<volume>2</volume>:<fpage>30ra32</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/scitranslmed.3000544" xlink:type="simple">10.1126/scitranslmed.3000544</ext-link></comment> <object-id pub-id-type="pmid">20445200</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Murakami</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Imamura</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Hayes</surname> <given-names>CN</given-names></name>, <name name-style="western"><surname>Abe</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Hiraga</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Honda</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin</article-title>. <source>Antimicrob Ag Chem</source>. <year>2014</year>;<volume>58</volume>:<fpage>2105</fpage>–<lpage>2112</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006335.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sarrazin</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Dvory-Sobol</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Svarovskaia</surname> <given-names>ES</given-names></name>, <name name-style="western"><surname>Doehle</surname> <given-names>BP</given-names></name>, <name name-style="western"><surname>Pang</surname> <given-names>PS</given-names></name>, <name name-style="western"><surname>Chuang</surname> <given-names>S-M</given-names></name>, <etal>et al</etal>. <article-title>Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir</article-title>. <source>Gastroenterology</source>. <year>2016</year>;<volume>151</volume>:<fpage>501</fpage>–<lpage>512.e501</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1053/j.gastro.2016.06.002" xlink:type="simple">10.1053/j.gastro.2016.06.002</ext-link></comment> <object-id pub-id-type="pmid">27296509</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Haller</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Kochs</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Weber</surname> <given-names>F</given-names></name>. <article-title>The interferon response circuit: Induction and suppression by pathogenic viruses</article-title>. <source>Virology</source>. <year>2006</year>;<volume>344</volume>:<fpage>119</fpage>–<lpage>130</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.virol.2005.09.024" xlink:type="simple">10.1016/j.virol.2005.09.024</ext-link></comment> <object-id pub-id-type="pmid">16364743</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Perelson</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Guedj</surname> <given-names>J</given-names></name>. <article-title>Modelling hepatitis C therapy-predicting effects of treatment</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. <year>2015</year>;<volume>12</volume>:<fpage>437</fpage>–<lpage>445</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrgastro.2015.97" xlink:type="simple">10.1038/nrgastro.2015.97</ext-link></comment> <object-id pub-id-type="pmid">26122475</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Padmanabhan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Garaigorta</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Dixit</surname> <given-names>NM</given-names></name>. <article-title>Emergent properties of the interferon-signalling network may underlie the success of hepatitis C treatment</article-title>. <source>Nat Commun</source>. <year>2014</year>;<volume>5</volume>:<fpage>3872</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ncomms4872" xlink:type="simple">10.1038/ncomms4872</ext-link></comment> <object-id pub-id-type="pmid">24834957</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Adiwijaya</surname> <given-names>BS</given-names></name>, <name name-style="western"><surname>Herrmann</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Hare</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Kieffer</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Kwong</surname> <given-names>AD</given-names></name>, <etal>et al</etal>. <article-title>A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants</article-title>. <source>PLoS Comput Biol</source>. <year>2010</year>;<volume>6</volume>:<fpage>e1000745</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pcbi.1000745" xlink:type="simple">10.1371/journal.pcbi.1000745</ext-link></comment> <object-id pub-id-type="pmid">20419154</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Haseltine</surname> <given-names>EL</given-names></name>, <name name-style="western"><surname>De Meyer</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Dierynck</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Bartels</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Ghys</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Davis</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Modeling viral evolutionary dynamics after telaprevir-based treatment</article-title>. <source>PLoS Comput Biol</source>. <year>2014</year>;<volume>10</volume>:<fpage>e1003772</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pcbi.1003772" xlink:type="simple">10.1371/journal.pcbi.1003772</ext-link></comment> <object-id pub-id-type="pmid">25101970</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Adiwijaya</surname> <given-names>BS</given-names></name>, <name name-style="western"><surname>Kieffer</surname> <given-names>TL</given-names></name>, <name name-style="western"><surname>Henshaw</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Eisenhauer</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kimko</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Alam</surname> <given-names>JJ</given-names></name>, <etal>et al</etal>. <article-title>A Viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection</article-title>. <source>PLoS Comput Biol</source>. <year>2012</year>;<volume>8</volume>:<fpage>e1002339</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pcbi.1002339" xlink:type="simple">10.1371/journal.pcbi.1002339</ext-link></comment> <object-id pub-id-type="pmid">22241977</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Powdrill</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Tchesnokov</surname> <given-names>EP</given-names></name>, <name name-style="western"><surname>Kozak</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Russell</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>Martin</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Svarovskaia</surname> <given-names>ES</given-names></name>, <etal>et al</etal>. <article-title>Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2011</year>;<volume>108</volume>:<fpage>20509</fpage>–<lpage>20513</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1105797108" xlink:type="simple">10.1073/pnas.1105797108</ext-link></comment> <object-id pub-id-type="pmid">22135458</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rong</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Ribeiro</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Perelson</surname> <given-names>AS</given-names></name>. <article-title>Modeling Quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor</article-title>. <source>Bull Math Biol</source>. <year>2012</year>;<volume>74</volume>:<fpage>1789</fpage>–<lpage>1817</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11538-012-9736-y" xlink:type="simple">10.1007/s11538-012-9736-y</ext-link></comment> <object-id pub-id-type="pmid">22639338</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guedj</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Dahari</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Rong</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Sansone</surname> <given-names>ND</given-names></name>, <name name-style="western"><surname>Nettles</surname> <given-names>RE</given-names></name>, <name name-style="western"><surname>Cotler</surname> <given-names>SJ</given-names></name>, <etal>et al</etal>. <article-title>Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2014</year>;<volume>110</volume>:<fpage>3991</fpage>–<lpage>3996</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006335.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Binder</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sulaimanov</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Clausznitzer</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Schulze</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>HÃ¼ber</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Lenz</surname> <given-names>SM</given-names></name>, <etal>et al</etal>. <article-title>Replication vesicles are load- and choke-points in the hepatitis C virus lifecycle</article-title>. <source>PLoS Pathog</source>. <year>2013</year>;<volume>9</volume>:<fpage>e1003561</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1003561" xlink:type="simple">10.1371/journal.ppat.1003561</ext-link></comment> <object-id pub-id-type="pmid">23990783</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rand</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Rinas</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Schwerk</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Nohren</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Linnes</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kroger</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Multi-layered stochasticity and paracrine signal propagation shape the type-I interferon response</article-title>. <source>Mol Sys Biol</source>. <year>2012</year>;<volume>8</volume>:<fpage>584</fpage>.</mixed-citation></ref>
<ref id="pcbi.1006335.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Herrmann</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Zeuzem</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sarrazin</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Hinrichsen</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Benhamou</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Manns</surname> <given-names>MP</given-names></name>, <etal>et al</etal>. <article-title>Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061</article-title>. <source>Antivir Ther</source>. <year>2006</year>;<volume>11</volume>:<fpage>371</fpage>. <object-id pub-id-type="pmid">16759054</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dahari</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Canini</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Graw</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Uprichard</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Araujo</surname> <given-names>ESA</given-names></name>, <name name-style="western"><surname>Penaranda</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir</article-title>. <source>J Hepatol</source>. <year>2016</year>;<volume>64</volume>:<fpage>1232</fpage>–<lpage>1239</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jhep.2016.02.022" xlink:type="simple">10.1016/j.jhep.2016.02.022</ext-link></comment> <object-id pub-id-type="pmid">26907973</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schoggins</surname> <given-names>JW</given-names></name>, <name name-style="western"><surname>Wilson</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Panis</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Murphy</surname> <given-names>MY</given-names></name>, <name name-style="western"><surname>Jones</surname> <given-names>CT</given-names></name>, <name name-style="western"><surname>Bieniasz</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>A diverse range of gene products are effectors of the type I interferon antiviral response</article-title>. <source>Nature</source>. <year>2011</year>;<volume>472</volume>:<fpage>481</fpage>–<lpage>485</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature09907" xlink:type="simple">10.1038/nature09907</ext-link></comment> <object-id pub-id-type="pmid">21478870</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Metz</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Dazert</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Ruggieri</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Mazur</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kaderali</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Kaul</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication</article-title>. <source>Hepatology</source>. <year>2012</year>;<volume>56</volume>:<fpage>2082</fpage>–<lpage>2093</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/hep.25908" xlink:type="simple">10.1002/hep.25908</ext-link></comment> <object-id pub-id-type="pmid">22711689</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Garaigorta</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Chisari</surname> <given-names>FV</given-names></name>. <article-title>Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation</article-title>. <source>Cell Host Microbe</source>. <year>2009</year>;<volume>6</volume>:<fpage>513</fpage>–<lpage>522</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.chom.2009.11.004" xlink:type="simple">10.1016/j.chom.2009.11.004</ext-link></comment> <object-id pub-id-type="pmid">20006840</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jarret</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>McFarland</surname> <given-names>AP</given-names></name>, <name name-style="western"><surname>Horner</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Kell</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Schwerk</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hong</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling</article-title>. <source>Nat Med</source>. <year>2016</year>;<volume>22</volume>:<fpage>1475</fpage>–<lpage>1481</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nm.4211" xlink:type="simple">10.1038/nm.4211</ext-link></comment> <object-id pub-id-type="pmid">27841874</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>WL</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>HC</given-names></name>, <name name-style="western"><surname>Hsu</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>TS</given-names></name>, <name name-style="western"><surname>Kao</surname> <given-names>JH</given-names></name>, <etal>et al</etal>. <article-title>Pegylated IFN-alpha suppresses hepatitis C virus by promoting the DAPK-mTOR pathway</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2016</year>;<volume>113</volume>:<fpage>14799</fpage>–<lpage>14804</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1618517114" xlink:type="simple">10.1073/pnas.1618517114</ext-link></comment> <object-id pub-id-type="pmid">27930338</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Qi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Chu</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>NC</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Truong</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Brar</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2017</year>;<volume>114</volume>:<fpage>2018</fpage>–<lpage>2023</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1614623114" xlink:type="simple">10.1073/pnas.1614623114</ext-link></comment> <object-id pub-id-type="pmid">28159892</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kandathil</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Graw</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Quinn</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hwang</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Torbenson</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Perelson</surname> <given-names>AS</given-names></name>, <etal>et al</etal>. <article-title>Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver</article-title>. <source>Gastroenterology</source>. <year>2013</year>;<volume>145</volume>:<fpage>1404</fpage>–<lpage>1413.e1410</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1053/j.gastro.2013.08.034" xlink:type="simple">10.1053/j.gastro.2013.08.034</ext-link></comment> <object-id pub-id-type="pmid">23973767</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kurbanov</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Latanich</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Chaudhari</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>El-Diwany</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Knabel</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>IFNL3 genotype is associated with differential induction of IFNL3 in primary human hepatocytes</article-title>. <source>Antivir Ther</source>. <year>2015</year>;<volume>20</volume>:<fpage>805</fpage>–<lpage>814</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3851/IMP2974" xlink:type="simple">10.3851/IMP2974</ext-link></comment> <object-id pub-id-type="pmid">26109548</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cribier</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Schmitt</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Rey</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Lang</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Kirn</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Stoll-Keller</surname> <given-names>F</given-names></name>. <article-title>Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfection by HIV and HCV</article-title>. <source>Res Virol</source>. <year>1996</year>;<volume>147</volume>:<fpage>263</fpage>–<lpage>266</lpage>. <object-id pub-id-type="pmid">8880995</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hayes</surname> <given-names>CN</given-names></name>, <name name-style="western"><surname>Imamura</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Aikata</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Chayama</surname> <given-names>K</given-names></name>. <article-title>Genetics of IL28B and HCV-response to infection and treatment</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. <year>2012</year>;<volume>9</volume>:<fpage>406</fpage>–<lpage>417</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrgastro.2012.101" xlink:type="simple">10.1038/nrgastro.2012.101</ext-link></comment> <object-id pub-id-type="pmid">22641049</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosenbloom</surname> <given-names>DIS</given-names></name>, <name name-style="western"><surname>Hill</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Rabi</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Siliciano</surname> <given-names>RF</given-names></name>, <name name-style="western"><surname>Nowak</surname> <given-names>MA</given-names></name>. <article-title>Antiretroviral dynamics determines HIV evolution and predicts therapy outcome</article-title>. <source>Nat Med</source>. <year>2012</year>;<volume>18</volume>:<fpage>1378</fpage>–<lpage>1385</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nm.2892" xlink:type="simple">10.1038/nm.2892</ext-link></comment> <object-id pub-id-type="pmid">22941277</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hare</surname> <given-names>BJ</given-names></name>, <name name-style="western"><surname>Haseltine</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Fleming</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Chelsky</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>McIntosh</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Allard</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>A signature for immune response correlates with HCV treatment outcome in Caucasian subjects</article-title>. <source>J Proteomics</source>. <year>2015</year>;<volume>116</volume>:<fpage>59</fpage>–<lpage>67</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jprot.2014.12.015" xlink:type="simple">10.1016/j.jprot.2014.12.015</ext-link></comment> <object-id pub-id-type="pmid">25576854</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Snoeck</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Chanu</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Lavielle</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Jacqmin</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Jonsson</surname> <given-names>EN</given-names></name>, <name name-style="western"><surname>Jorga</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>A comprehensive hepatitis C viral kinetic model explaining cure</article-title>. <source>Clin Pharmacol Ther</source>. <year>2010</year>;<volume>87</volume>:<fpage>706</fpage>–<lpage>713</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/clpt.2010.35" xlink:type="simple">10.1038/clpt.2010.35</ext-link></comment> <object-id pub-id-type="pmid">20463660</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thimme</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Binder</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bartenschlager</surname> <given-names>R</given-names></name>. <article-title>Failure of innate and adaptive immune responses in controlling hepatitis C virus infection</article-title>. <source>FEMS Microbiol Rev</source>. <year>2012</year>;<volume>36</volume>:<fpage>663</fpage>–<lpage>683</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1574-6976.2011.00319.x" xlink:type="simple">10.1111/j.1574-6976.2011.00319.x</ext-link></comment> <object-id pub-id-type="pmid">22142141</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Perales</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Beach</surname> <given-names>NM</given-names></name>, <name name-style="western"><surname>Gallego</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Soria</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Quer</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Esteban</surname> <given-names>JI</given-names></name>, <etal>et al</etal>. <article-title>Response of hepatitis C virus to long-term passage in the presence of interferon-alpha. Multiple mutations and a common phenotype</article-title>. <source>J Virol</source>. <year>2013</year>;<volume>87</volume>:<fpage>7593</fpage>–<lpage>7607</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JVI.02824-12" xlink:type="simple">10.1128/JVI.02824-12</ext-link></comment> <object-id pub-id-type="pmid">23637397</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wieland</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Makowska</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Campana</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Calabrese</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Dill</surname> <given-names>MT</given-names></name>, <name name-style="western"><surname>Chung</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver</article-title>. <source>Hepatology</source>. <year>2013</year>;<volume>59</volume>:<fpage>2121</fpage>–<lpage>2130</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006335.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nainan</surname> <given-names>OV</given-names></name>, <name name-style="western"><surname>Alter</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Kruszon-Moran</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Gao</surname> <given-names>F-X</given-names></name>, <name name-style="western"><surname>Xia</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>McQuillan</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States</article-title>. <source>Gastroenterology</source>. <year>2006</year>;<volume>131</volume>:<fpage>478</fpage>–<lpage>484</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1053/j.gastro.2006.06.007" xlink:type="simple">10.1053/j.gastro.2006.06.007</ext-link></comment> <object-id pub-id-type="pmid">16890602</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Micallef</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Kaldor</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Dore</surname> <given-names>GJ</given-names></name>. <article-title>Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies</article-title>. <source>J Viral Hep</source>. <year>2006</year>;<volume>13</volume>:<fpage>34</fpage>–<lpage>41</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006335.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sarrazin</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Kieffer</surname> <given-names>TL</given-names></name>, <name name-style="western"><surname>Bartels</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Hanzelka</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Muh</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Welker</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir</article-title>. <source>Gastroenterology</source>. <year>2007</year>;<volume>132</volume>:<fpage>1767</fpage>–<lpage>1777</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1053/j.gastro.2007.02.037" xlink:type="simple">10.1053/j.gastro.2007.02.037</ext-link></comment> <object-id pub-id-type="pmid">17484874</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Suzuki</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Suzuki</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Akuta</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Sezaki</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Yatsuji</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Arase</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir</article-title>. <source>J Clin Virol</source>. <year>2010</year>;<volume>47</volume>:<fpage>76</fpage>–<lpage>78</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jcv.2009.09.029" xlink:type="simple">10.1016/j.jcv.2009.09.029</ext-link></comment> <object-id pub-id-type="pmid">19857995</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref048"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Vertex. Incivek highlights of prescribing information. <ext-link ext-link-type="uri" xlink:href="http://pivrtxcom/files/uspi_telaprevirpdf" xlink:type="simple">http://pivrtxcom/files/uspi_telaprevirpdf</ext-link>. 2013.</mixed-citation></ref>
<ref id="pcbi.1006335.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ferenci</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Fried</surname> <given-names>MW</given-names></name>, <name name-style="western"><surname>Shiffman</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>CI</given-names></name>, <name name-style="western"><surname>Marinos</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Goncales</surname> <given-names>FL</given-names> <suffix>Jr.</suffix></name>, <etal>et al</etal>. <article-title>Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a /ribavirin</article-title>. <source>J Hepatol</source>. <year>2005</year>;<volume>43</volume>:<fpage>425</fpage>–<lpage>433</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jhep.2005.04.009" xlink:type="simple">10.1016/j.jhep.2005.04.009</ext-link></comment> <object-id pub-id-type="pmid">15990196</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xiao</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Fofana</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Thumann</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Mailly</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Alles</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Robinet</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C</article-title>. <source>Gut</source>. <year>2014</year>;<volume>64</volume>:<fpage>483</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/gutjnl-2013-306155" xlink:type="simple">10.1136/gutjnl-2013-306155</ext-link></comment> <object-id pub-id-type="pmid">24848265</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Padmanabhan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Dixit</surname> <given-names>NM</given-names></name>. <article-title>Modeling suggests a mechanism of synergy between hepatitis C virus entry inhibitors and drugs of other classes</article-title>. <source>CPT: Pharm Sys Pharm</source>. <year>2015</year>;<volume>4</volume>:<fpage>445</fpage>–<lpage>453</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006335.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Alton</surname> <given-names>G</given-names></name>. <article-title>Submission to the United Nations Secretary-General’s high-level panel on access to medicines</article-title>. <source>Gilead Sciences</source>; <year>2016</year> (<ext-link ext-link-type="uri" xlink:href="http://www.unsgaccessmeds.org/inbox/2016/2/29/gilead-sciences-inc" xlink:type="simple">http://www.unsgaccessmeds.org/inbox/2016/2/29/gilead-sciences-inc</ext-link>). 2016.</mixed-citation></ref>
<ref id="pcbi.1006335.ref053"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">UNITAID. Hepatitis C medicines: technology and market landscape–update. <ext-link ext-link-type="uri" xlink:href="http://wwwunitaideu/images/marketdynamics/publications/Hepatitis_C_Medicines_Technology_and_Market_Landscape__Updatepdf" xlink:type="simple">http://wwwunitaideu/images/marketdynamics/publications/Hepatitis_C_Medicines_Technology_and_Market_Landscape__Updatepdf</ext-link>. 2015.</mixed-citation></ref>
<ref id="pcbi.1006335.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Koizumi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ohashi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Nakajima</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wakita</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Perelson</surname> <given-names>AS</given-names></name>, <etal>et al</etal>. <article-title>Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2017</year>;<volume>114</volume>:<fpage>1922</fpage>–<lpage>1927</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1610197114" xlink:type="simple">10.1073/pnas.1610197114</ext-link></comment> <object-id pub-id-type="pmid">28174263</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ohashi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Koizumi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Fukano</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Wakita</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Perelson</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Iwami</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2017</year>;<volume>114</volume>:<fpage>E4527</fpage>–<lpage>E4529</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1705234114" xlink:type="simple">10.1073/pnas.1705234114</ext-link></comment> <object-id pub-id-type="pmid">28512226</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Padmanabhan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Dixit</surname> <given-names>NM</given-names></name>. <article-title>Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2017</year>;<volume>114</volume>:<fpage>E4524</fpage>–<lpage>E4526</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1704531114" xlink:type="simple">10.1073/pnas.1704531114</ext-link></comment> <object-id pub-id-type="pmid">28512229</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lau</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Benhamou</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Shao</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Ji</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study</article-title>. <source>Lancet Gastroenterol Hepatol</source>. <year>2016</year>;<volume>1</volume>:<fpage>97</fpage>–<lpage>104</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S2468-1253(16)30015-2" xlink:type="simple">10.1016/S2468-1253(16)30015-2</ext-link></comment> <object-id pub-id-type="pmid">27917405</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aghemo</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Colombo</surname> <given-names>M</given-names></name>. <article-title>Response-guided duration of direct acting antiviral therapy for chronic hepatitis C: Back to the future?</article-title> <source>Gastroenterology</source>. <year>2017</year>;<volume>152</volume>:<fpage>1238</fpage>–<lpage>1239</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1053/j.gastro.2017.02.022" xlink:type="simple">10.1053/j.gastro.2017.02.022</ext-link></comment> <object-id pub-id-type="pmid">28253477</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kohli</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Osinusi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Sims</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Nelson</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Meissner</surname> <given-names>EG</given-names></name>, <name name-style="western"><surname>Barrett</surname> <given-names>LL</given-names></name>, <etal>et al</etal>. <article-title>Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study</article-title>. <source>Lancet</source>. <year>2015</year>;<volume>385</volume>:<fpage>1107</fpage>–<lpage>1113</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(14)61228-9" xlink:type="simple">10.1016/S0140-6736(14)61228-9</ext-link></comment> <object-id pub-id-type="pmid">25591505</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref060"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maasoumy</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Vermehren</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Welker</surname> <given-names>M-W</given-names></name>, <name name-style="western"><surname>Bremer</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Perner</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Honer zu Siederdissen</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens</article-title>. <source>J Hepatol</source>. <year>2016</year>;<volume>65</volume>:<fpage>473</fpage>–<lpage>482</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jhep.2016.04.006" xlink:type="simple">10.1016/j.jhep.2016.04.006</ext-link></comment> <object-id pub-id-type="pmid">27085252</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref061"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>El Sherif</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Afhdal</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Curry</surname> <given-names>M</given-names></name>. <article-title>No one size fits all—shortening duration of therapy with direct acting antivirals for hepatitis C genotype 1 infection</article-title>. <source>J Viral Hepatitis</source>. <year>2017</year>;<volume>24</volume>:<fpage>808</fpage>–<lpage>813</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006335.ref062"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tsubota</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Arase</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Someya</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Suzuki</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Suzuki</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Saitoh</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naïve patients infected with hepatitis C virus of genotype 1b and high viral load</article-title>. <source>J Med Virol</source>. <year>2005</year>;<volume>75</volume>:<fpage>27</fpage>–<lpage>34</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jmv.20232" xlink:type="simple">10.1002/jmv.20232</ext-link></comment> <object-id pub-id-type="pmid">15543591</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref063"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Makiyama</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Itoh</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Yasui</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Mori</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Okita</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Nakayama</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C</article-title>. <source>Hepatol Res</source>. <year>2006</year>;<volume>36</volume>:<fpage>94</fpage>–<lpage>99</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.hepres.2006.07.001" xlink:type="simple">10.1016/j.hepres.2006.07.001</ext-link></comment> <object-id pub-id-type="pmid">16950651</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref064"><label>64</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rong</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Guedj</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Dahari</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Perelson</surname> <given-names>AS</given-names></name>. <article-title>Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling</article-title>. <source>Antivir Ther</source>. <year>2014</year>;<volume>19</volume>:<fpage>469</fpage>–<lpage>477</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3851/IMP2725" xlink:type="simple">10.3851/IMP2725</ext-link></comment> <object-id pub-id-type="pmid">24434478</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref065"><label>65</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hezode</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Chevaliez</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Scoazec</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Bouvier-Alias</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ruiz</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Francois</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>On-treatment viral kinetics do not predict SVR in patients with advanced liver disease receiving sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks</article-title>. <source>J Hepatol</source>. <year>2015</year>;<volume>62</volume>:<fpage>S654</fpage>–<lpage>S655</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006335.ref066"><label>66</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fourati</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Guedj</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Chevaliez</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Nguyen</surname> <given-names>T H T</given-names></name>, <name name-style="western"><surname>Roudot-Thoraval</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Ruiz</surname> <given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor</article-title>. <source>Aliment Pharm Ther</source>. <year>2018</year>;<volume>47</volume>:<fpage>665</fpage>–<lpage>673</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006335.ref067"><label>67</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Howe</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Long</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Black</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chase</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>McMonagle</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Curry</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Clinical implications of detectable baseline hepatitis C virus-genotype 1 NS3/4A-protease variants on the efficacy of boceprevir combined with peginterferon/ribavirin</article-title>. <source>Open Forum Inf Dis</source>. <year>2014</year>;<volume>1</volume>:<fpage>ofu078</fpage>.</mixed-citation></ref>
<ref id="pcbi.1006335.ref068"><label>68</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>De Meyer</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Dierynck</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Ghys</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Beumont</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Daems</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Van Baelen</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial</article-title>. <source>Hepatology</source>. <year>2012</year>;<volume>56</volume>:<fpage>2106</fpage>–<lpage>2115</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/hep.25962" xlink:type="simple">10.1002/hep.25962</ext-link></comment> <object-id pub-id-type="pmid">22806681</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref069"><label>69</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sun</surname> <given-names>J-H</given-names></name>, <name name-style="western"><surname>O'Boyle</surname> <given-names>II DR</given-names></name>, <name name-style="western"><surname>Fridell</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Langley</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Roberts</surname> <given-names>SB</given-names></name>, <etal>et al</etal>. <article-title>Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A</article-title>. <source>Nature</source>. <year>2015</year>;<volume>527</volume>:<fpage>245</fpage>–<lpage>248</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature15711" xlink:type="simple">10.1038/nature15711</ext-link></comment> <object-id pub-id-type="pmid">26536115</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref070"><label>70</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Malespin</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Benyashvili</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Uprichard</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Perelson</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Dahari</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Cotler</surname> <given-names>SJ</given-names></name>. <article-title>Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies</article-title>. <source>Therap Adv Gastroenterol</source>. <year>2017</year>;<volume>10</volume>:<fpage>68</fpage>–<lpage>73</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/1756283X16672392" xlink:type="simple">10.1177/1756283X16672392</ext-link></comment> <object-id pub-id-type="pmid">28286560</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref071"><label>71</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nguyen</surname> <given-names>THT</given-names></name>, <name name-style="western"><surname>Guedj</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Uprichard</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Kohli</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kottilil</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Perelson</surname> <given-names>AS</given-names></name>. <article-title>The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?</article-title> <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>:<fpage>10233</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41598-017-09776-z" xlink:type="simple">10.1038/s41598-017-09776-z</ext-link></comment> <object-id pub-id-type="pmid">28860456</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref072"><label>72</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Goyal</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lurie</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Meissner</surname> <given-names>EG</given-names></name>, <name name-style="western"><surname>Major</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sansone</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Uprichard</surname> <given-names>SL</given-names></name>, <etal>et al</etal>. <article-title>Modeling HCV cure after an ultra-short duration of therapy with direct acting agents</article-title>. <source>Antiviral Res</source>. <year>2017</year>;<volume>144</volume>:<fpage>281</fpage>–<lpage>285</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.antiviral.2017.06.019" xlink:type="simple">10.1016/j.antiviral.2017.06.019</ext-link></comment> <object-id pub-id-type="pmid">28673800</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref073"><label>73</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Baral</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Roy</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Dixit</surname> <given-names>NM</given-names></name>. <article-title>Modelling how reversal of immune exhaustion elicits cure of chronic hepatitis C after the end of treatment with direct‐acting antiviral agents</article-title>. <source>Immunol Cell Biol</source>. <year>2018</year>; <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/imcb.12161" xlink:type="simple">https://doi.org/10.1111/imcb.12161</ext-link></mixed-citation></ref>
<ref id="pcbi.1006335.ref074"><label>74</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Padmanabhan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Dixit</surname> <given-names>NM</given-names></name>. <article-title>Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry</article-title>. <source>PLoS Comput Biol</source>. <year>2011</year>;<volume>7</volume>:<fpage>e1002307</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pcbi.1002307" xlink:type="simple">10.1371/journal.pcbi.1002307</ext-link></comment> <object-id pub-id-type="pmid">22174670</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref075"><label>75</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ribeiro</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Bonhoeffer</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Nowak</surname> <given-names>MA</given-names></name>. <article-title>The frequency of resistant mutant virus before antiviral therapy</article-title>. <source>AIDS</source>. <year>1998</year>;<volume>12</volume>:<fpage>461</fpage>–<lpage>465</lpage>. <object-id pub-id-type="pmid">9543443</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref076"><label>76</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Marino</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Hogue</surname> <given-names>IB</given-names></name>, <name name-style="western"><surname>Ray</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Kirschner</surname> <given-names>DE</given-names></name>. <article-title>A methodology for performing global uncertainty and sensitivity analysis in systems biology</article-title>. <source>J Theor Biol</source>. <year>2008</year>;<volume>254</volume>:<fpage>178</fpage>–<lpage>196</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jtbi.2008.04.011" xlink:type="simple">10.1016/j.jtbi.2008.04.011</ext-link></comment> <object-id pub-id-type="pmid">18572196</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref077"><label>77</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Qi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Olson</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>NC</given-names></name>, <name name-style="western"><surname>Ke</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Loverdo</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Chu</surname> <given-names>V</given-names></name>, <etal>et al</etal>. <article-title>A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity</article-title>. <source>PLoS Pathog</source>. <year>2014</year>;<volume>10</volume>:<fpage>e1004064</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.ppat.1004064" xlink:type="simple">10.1371/journal.ppat.1004064</ext-link></comment> <object-id pub-id-type="pmid">24722365</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref078"><label>78</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fridell</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>J-H</given-names></name>, <name name-style="western"><surname>O'Boyle</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Nower</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Valera</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations</article-title>. <source>Hepatology</source>. <year>2011</year>;<volume>54</volume>:<fpage>1924</fpage>–<lpage>1935</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/hep.24594" xlink:type="simple">10.1002/hep.24594</ext-link></comment> <object-id pub-id-type="pmid">21809362</object-id></mixed-citation></ref>
<ref id="pcbi.1006335.ref079"><label>79</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nettles</surname> <given-names>RE</given-names></name>, <name name-style="western"><surname>Gao</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bifano</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Chung</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Persson</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Marbury</surname> <given-names>TC</given-names></name>, <etal>et al</etal>. <article-title>Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1</article-title>. <source>Hepatology</source>. <year>2011</year>;<volume>54</volume>:<fpage>1956</fpage>–<lpage>1965</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/hep.24609" xlink:type="simple">10.1002/hep.24609</ext-link></comment> <object-id pub-id-type="pmid">21837752</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>